https://www.farmacovigilanzasardegna.it/2012/12/21/ponatinib-nel-trattamento-di-leucemie-cromosoma-philadelphia-positive-ph-resistenti/ 2012-12-21T11:15:15+00:00 https://www.farmacovigilanzasardegna.it/2013/01/03/complessi-proteolitici-batterici-come-targets-terapeutici/ 2013-01-03T15:06:29+00:00 https://www.farmacovigilanzasardegna.it/2013/01/11/associazione-tra-lefficacia-del-litio-nel-trattamento-di-mantenimento-del-disturbo-bipolare-e-i-livelli-plasmatici-di-litio/ 2013-01-11T09:28:51+00:00 https://www.farmacovigilanzasardegna.it/2013/01/14/predizione-e-test-dellattivita-farmacologica-sui-bersagli-degli-effetti-collaterali/ 2013-01-14T10:25:29+00:00 https://www.farmacovigilanzasardegna.it/2013/01/14/la-crisi-dellassenza-di-nuovi-antibiotici-qual-e-la-via-da-seguire/ 2013-01-14T10:29:22+00:00 https://www.farmacovigilanzasardegna.it/2013/01/21/aggiornamento-sulla-farmaco-genomica-della-sclerosi-multipla-focus-su-strategie-terapeutiche-in-uso-e-novita/ 2013-01-21T10:22:23+00:00 https://www.farmacovigilanzasardegna.it/2013/01/22/amoxicillina-per-infezioni-acute-del-tratto-respiratorio-inferiore-senza-sospetto-di-polmonite-uno-studio-randomizzato-controllato-con-placebo/ 2013-01-22T11:16:31+00:00 https://www.farmacovigilanzasardegna.it/2013/01/28/uso-concomitante-di-diuretici-ace-inibitori-e-sartani-con-antinfiammatori-non-steroidei-fans-e-rischio-di-danno-renale-acuto-uno-studio-nested-caso-controllo/ 2013-01-28T09:09:26+00:00 https://www.farmacovigilanzasardegna.it/2013/01/28/aggiornamento-della-agenzia-europea-dei-medicinali-sui-contraccettivi-combinati/ 2013-01-28T13:29:46+00:00 https://www.farmacovigilanzasardegna.it/2013/02/04/importante-danno-epatico-associato-con-luso-di-tolvaptan/ 2013-02-04T12:31:22+00:00 https://www.farmacovigilanzasardegna.it/2013/02/04/eventi-avversi-neuropsichiatrici-della-vareniclina-revisione-sistematica-dei-casi-pubblicati/ 2013-02-04T12:39:13+00:00 https://www.farmacovigilanzasardegna.it/2013/02/11/trastuzumab-e-gravidanza-una-revisione-sistematica-e-metanalisi/ 2013-02-11T08:59:59+00:00 https://www.farmacovigilanzasardegna.it/2013/02/12/reazioni-avverse-a-gabapentin-e-pregabalin-revisione-dei-dati-provenienti-dal-database-di-farmacovigilanza-francese/ 2013-02-12T13:00:39+00:00 https://www.farmacovigilanzasardegna.it/2013/02/18/comunicato-stampa-della-agenzia-europea-dei-medicinali-ema-relativo-allavvio-di-una-revisione-su-diane-35-e-su-altri-medicinali-contenenti-ciproterone-acetato-2-mg-ed-etinilestradiolo-35-mi/ 2013-02-18T11:40:28+00:00 https://www.farmacovigilanzasardegna.it/2013/02/19/intervallo-qt-e-uso-di-antidepressivi-studio-trasversale-condotto-attraverso-cartelle-cliniche-elettroniche-2/ 2013-02-19T10:35:07+00:00 https://www.farmacovigilanzasardegna.it/2013/02/26/esposizione-a-bifosfonati-e-rischio-di-tumori-gastrointestinali/ 2013-02-26T11:28:45+00:00 https://www.farmacovigilanzasardegna.it/2013/02/26/nota-informativa-aifa-importante-su-neurobloc-tossina-botulinica-di-tipob/ 2013-02-26T12:21:25+00:00 https://www.farmacovigilanzasardegna.it/2013/02/26/nota-informativa-aifa-importante-su-prolia-denosumab/ 2013-02-26T12:24:23+00:00 https://www.farmacovigilanzasardegna.it/2013/03/11/nota-informativa-aifa-importante-su-vistide-cidofovir/ 2013-03-11T10:11:49+00:00 https://www.farmacovigilanzasardegna.it/2013/03/11/opportunita-per-ridurre-in-maniera-significativa-la-complessita-delle-terapie-farmacologiche/ 2013-03-11T12:15:19+00:00 https://www.farmacovigilanzasardegna.it/2013/03/12/nota-informativa-aifa-importante-su-optimark-gadoversetamide/ 2013-03-12T10:08:45+00:00 https://www.farmacovigilanzasardegna.it/2013/03/15/la-durata-del-trattamento-con-litio-rappresenta-un-fattore-di-rischio-per-la-riduzione-della-filtrazione-glomerulare-studio-cross-sectional/ 2013-03-15T13:00:03+00:00 https://www.farmacovigilanzasardegna.it/2013/03/19/comunicato-stampa-aifa-sulluso-intravitreale-del-medicinale-lucentis-ranibizumab/ 2013-03-19T12:48:53+00:00 https://www.farmacovigilanzasardegna.it/2013/03/19/elementi-chiave-nei-segnali-di-adr-da-interazioni-tra-farmaci/ 2013-03-19T12:52:05+00:00 https://www.farmacovigilanzasardegna.it/2013/03/26/nota-informativa-aifa-importante-su-mimpara-cinacalcet/ 2013-03-26T13:09:37+00:00 https://www.farmacovigilanzasardegna.it/2013/03/26/nota-informativa-aifa-importante-su-nulojix-belatacept/ 2013-03-26T16:45:04+00:00 https://www.farmacovigilanzasardegna.it/2013/04/09/nota-informativa-aifa-importante-su-relpax-eletriptan-bromidrato/ 2013-04-09T12:04:09+00:00 https://www.farmacovigilanzasardegna.it/2013/04/09/nota-informativa-aifa-importante-sulla-gestione-delle-reazioni-avverse-cutanee-gravi-scar-associate-a-incivo-telaprevir-2/ 2013-04-09T12:06:46+00:00 https://www.farmacovigilanzasardegna.it/2013/04/09/nota-informativa-aifa-importante-su-xgeva-denosumab/ 2013-04-09T13:01:12+00:00 https://www.farmacovigilanzasardegna.it/2013/04/12/associazione-tra-uso-materno-di-integratori-a-base-di-acido-folico-e-rischio-di-disturbi-dello-spettro-autistico-nei-bambini/ 2013-04-12T12:56:55+00:00 https://www.farmacovigilanzasardegna.it/2013/04/29/uso-di-statine-ad-alta-potenza-e-tasso-di-ospedalizzazione-per-danni-renali/ 2013-04-29T15:48:42+00:00 https://www.farmacovigilanzasardegna.it/2013/04/29/aifa-nota-informativa-importante-su-mabthera-rituximab/ 2013-04-29T15:50:45+00:00 https://www.farmacovigilanzasardegna.it/2013/04/29/aifa-nota-informativa-importante-su-thalidomide-celgene/ 2013-04-29T15:53:08+00:00 https://www.farmacovigilanzasardegna.it/2013/05/14/aifa-nota-informativa-importante-su-pletal-cilostazolo/ 2013-05-14T15:40:54+00:00 https://www.farmacovigilanzasardegna.it/2013/05/14/fda-drug-safety-communication-sullantiepilettico-valproato/ 2013-05-14T15:43:23+00:00 https://www.farmacovigilanzasardegna.it/2013/05/14/variabilita-nelle-informazioni-sulla-safety-di-farmaci-ad-alto-consumo-in-diversi-contesti-nazionali/ 2013-05-14T15:46:10+00:00 https://www.farmacovigilanzasardegna.it/2013/05/17/il-fattore-di-crescita-insulino-simile-1-igf-1-e-sovraespresso-in-linee-cellulari-linfoblastoidi-di-pazienti-affetti-da-disturbo-bipolare-che-rispondono-al-litio/ 2013-05-17T15:36:51+00:00 https://www.farmacovigilanzasardegna.it/2013/05/21/medicinali-sottoposti-a-monitoraggio-addizionale-pubblicata-la-prima-lista/ 2013-05-21T15:33:34+00:00 https://www.farmacovigilanzasardegna.it/2013/05/28/ema-comunicato-stampa-su-diane-35-e-i-suoi-generici/ 2013-05-28T15:13:30+00:00 https://www.farmacovigilanzasardegna.it/2013/05/28/nuove-importanti-restrizioni-alluso-di-protelososseor-ranelato-di-stronzio-a-seguito-di-nuovi-dati-che-mostrano-un-aumentato-rischio-di-infarto-del-miocardio/ 2013-05-28T15:17:03+00:00 https://www.farmacovigilanzasardegna.it/2013/06/04/raccomandazione-dellema-di-limitare-luso-di-trobalt-allultima-linea-di-trattamento-delle-crisi-epilettiche-parziali/ 2013-06-04T15:04:51+00:00 https://www.farmacovigilanzasardegna.it/2013/06/04/rischio-di-diabete-di-nuova-insorgenza-in-pazienti-trattati-con-statine-studio-di-coorte-condotto-sulla-popolazione-2/ 2013-06-04T15:07:34+00:00 https://www.farmacovigilanzasardegna.it/2013/06/11/effetti-cardiovascolari-e-sul-tratto-gastrointestinale-superiore-dei-farmaci-anti-infiammatori-non-steroidei-meta-analisi-condotta-sui-dati-individuali-di-studi-randomizzati-2/ 2013-06-11T14:41:53+00:00 https://www.farmacovigilanzasardegna.it/2013/06/11/i-segnali-di-farmacovigilanza-rupatadina-ed-alterazioni-della-frequenza-e-del-ritmo-cardiaco/ 2013-06-11T14:45:22+00:00 https://www.farmacovigilanzasardegna.it/2013/06/11/1322-2/ 2013-06-11T14:55:39+00:00 https://www.farmacovigilanzasardegna.it/2013/06/11/sindrome-di-stevens-johnson-necrolisi-epidermica-tossica-i-testi-di-farmacologia-dedicati-sono-in-grado-di-informare-correttamente-i-medici-relativamente-ai-rischi/ 2013-06-11T15:01:31+00:00 https://www.farmacovigilanzasardegna.it/2013/06/14/farmaci-antipsicotici-di-seconda-generazione-e-rischio-di-polmonite-nella-schizofrenia/ 2013-06-14T14:30:25+00:00 https://www.farmacovigilanzasardegna.it/2013/06/24/le-pagine-del-paziente-pubblicate-su-jama-luso-improprio-di-farmaci-oppioidi-2/ 2013-06-24T14:21:46+00:00 https://www.farmacovigilanzasardegna.it/2013/06/24/oppioidi-per-il-dolore-cronico-non-oncologico/ 2013-06-24T14:27:35+00:00 https://www.farmacovigilanzasardegna.it/2013/07/01/omega-3-in-pazienti-con-fattori-di-rischio-cardiovascolare-multipli/ 2013-07-01T22:39:08+00:00 https://www.farmacovigilanzasardegna.it/2013/07/09/antiepilettici-diversi-da-gabapentin-pregabalin-topiramato-e-valproato-nella-profilassi-dellemicrania-episodica-negli-adulti/ 2013-07-09T22:31:28+00:00 https://www.farmacovigilanzasardegna.it/2013/07/09/rischio-di-insorgenza-di-diabete-tra-pazienti-trattati-con-statine-studio-basato-sulla-popolazione/ 2013-07-09T22:36:38+00:00 https://www.farmacovigilanzasardegna.it/2013/07/12/effetto-del-litio-sullespressione-dellenzima-spermidinaspermina-n1-acetiltransferasi-nel-comportamento-suicidario/ 2013-07-12T22:29:33+00:00 https://www.farmacovigilanzasardegna.it/2013/07/16/sintomi-neuropsichiatrici-associati-alluso-di-vareniclina-uno-studio-in-medicina-generale-in-inghilterra/ 2013-07-16T22:26:07+00:00 https://www.farmacovigilanzasardegna.it/2013/07/17/ema-misure-per-la-sicurezza-dei-farmaci-contenenti-codeina-flupirtina-diclofenac-ed-ergot/ 2013-07-17T22:22:21+00:00 https://www.farmacovigilanzasardegna.it/2013/07/22/tollerabilita-e-danni-delle-singole-statine-a-confronto-una-meta-analisi-di-246-955-partecipanti-da-135-randomized-controlled-trials/ 2013-07-22T22:02:55+00:00 https://www.farmacovigilanzasardegna.it/2013/07/22/trattamento-con-inibitori-dellenzima-di-conversione-dellangiotensina-ace-e-sviluppo-di-infezioni-del-tratto-urinario-unanalisi-di-simmetria-delle-prescrizioni/ 2013-07-22T22:19:26+00:00 https://www.farmacovigilanzasardegna.it/2013/07/29/lesposizione-del-feto-agli-inibitori-selettivi-della-ricaptazione-della-serotonina-ssri-o-la-depressione-materna-possono-influire-sullo-sviluppo-del-bambino/ 2013-07-29T21:58:28+00:00 https://www.farmacovigilanzasardegna.it/2013/07/29/ipersensibilita-allallopurinolo-una-revisione-sistematica-di-tutti-i-casi-pubblicati-1950-2012/ 2013-07-29T22:00:33+00:00 https://www.farmacovigilanzasardegna.it/2013/08/01/quando-decidere-di-sospendere-un-trattamento-farmacologico-la-sospensione-della-prescrizione-di-medicinali-deprescribing-basata-sulle-prove-defficacia-nella-popolazione-anziana/ 2013-08-01T21:46:13+00:00 https://www.farmacovigilanzasardegna.it/2013/08/05/misure-per-la-sicurezza-dei-farmaci-contenenti-votrient-pazopanib-codeina-metoclopramide-ketoconazolo-e-risultati-della-revisione-sulle-terapie-a-base-di-glp-1/ 2013-08-05T21:50:50+00:00 https://www.farmacovigilanzasardegna.it/2013/08/08/farmacovigilanza-e-biosimilari-considerazioni-necessita-e-sfide/ 2013-08-08T21:41:15+00:00 https://www.farmacovigilanzasardegna.it/2013/08/08/inibitori-della-dipeptidil-peptidasi-4-e-rischio-cardiovascolare-una-meta-analisi-di-casi-clinici-randomizzati/ 2013-08-08T21:44:28+00:00 https://www.farmacovigilanzasardegna.it/2013/08/19/il-litio-nella-prevenzione-del-suicidio-in-pazienti-affetti-da-disturbi-dellumore-review-sistematica-e-meta-analisi/ 2013-08-19T21:38:23+00:00 https://www.farmacovigilanzasardegna.it/2013/08/22/misure-per-la-sicurezza-dei-farmaci-vectibix-panitumumab-clopidogrel-citarabina-hospira-erwinase-lotto-160g-e-ketoconazolo-per-via-orale/ 2013-08-22T21:30:29+00:00 https://www.farmacovigilanzasardegna.it/2013/08/22/differenze-e-similarita-tra-farmaci-equivalenti-ed-originator-e-benefici-economici-associati-al-loro-uso-il-caso-dellirlanda/ 2013-08-22T21:36:22+00:00 https://www.farmacovigilanzasardegna.it/2013/09/04/terapia-con-triptani-ed-eventi-avversi-vascolari-gravi-analisi-del-data-base-delle-reazioni-avverse-della-food-and-drug-administration-degli-stati-uniti-fda_aers/ 2013-09-04T21:21:13+00:00 https://www.farmacovigilanzasardegna.it/2013/09/09/rischio-di-sviluppare-il-cancro-al-colon-retto-dopo-linizio-della-terapia-con-orlistat-tetraidrolipostatina/ 2013-09-09T21:19:01+00:00 https://www.farmacovigilanzasardegna.it/2013/09/09/lesposizione-alla-vareniclina-farmaco-per-la-cessazione-del-fumo-durante-la-gravidanza-uno-studio-di-coorte-prospettico-condotto-in-nuova-zelanda/ 2013-09-09T21:27:11+00:00 https://www.farmacovigilanzasardegna.it/2013/09/10/esiti-di-efficacia-e-sicurezza-di-anticoagulanti-orali-e-antiaggreganti-piastrinici-nella-prevenzione-secondaria-del-tromboembolismo-venoso-una-review-sistematica-e-metanalisi-di-confronto-di-trattam/ 2013-09-10T21:13:24+00:00 https://www.farmacovigilanzasardegna.it/2013/09/10/case-report-una-donna-di-54-anni-con-dolore-addominale-vomito-e-confusione/ 2013-09-10T21:23:35+00:00 https://www.farmacovigilanzasardegna.it/2013/09/17/tremore-da-litio-fisiopatologia-e-trattamento/ 2013-09-17T21:06:38+00:00 https://www.farmacovigilanzasardegna.it/2013/09/17/fda-lacetaminofene-paracetamolo-puo-provocare-gravi-reazioni-cutanee/ 2013-09-17T21:09:43+00:00 https://www.farmacovigilanzasardegna.it/2013/10/03/rapporto-osmed-2012/ 2013-10-03T19:00:22+00:00 https://www.farmacovigilanzasardegna.it/2013/10/03/andamento-delle-segnalazioni-di-sospette-reazioni-avverse-in-italia-dal-2001-al-2012/ 2013-10-03T21:03:42+00:00 https://www.farmacovigilanzasardegna.it/2013/10/10/aifa-rapporto-sulla-sorveglianza-postmarketing-dei-vaccini-in-italia-anno-2012/ 2013-10-10T14:27:02+00:00 https://www.farmacovigilanzasardegna.it/2013/10/10/aifa-nota-informativa-importante-su-ketoprofene/ 2013-10-10T20:59:30+00:00 https://www.farmacovigilanzasardegna.it/2013/10/24/fumo-di-sigaretta-durante-la-gravidanza-e-disturbo-bipolare-nei-figli/ 2013-10-24T14:24:09+00:00 https://www.farmacovigilanzasardegna.it/2013/10/28/malattie-cardiache-ischemiche-influenza-e-vaccinazione-contro-linfluenza-uno-studio-caso-controllo-prospettico/ 2013-10-28T14:20:11+00:00 https://www.farmacovigilanzasardegna.it/2013/10/28/una-sindrome-sottodiagnosticata-la-sindrome-di-kounis-scatenata-da-amoxicillinaacido-clavulanico/ 2013-10-28T14:22:22+00:00 https://www.farmacovigilanzasardegna.it/2013/11/14/uso-della-metoclopramide-in-gravidanza-e-rischio-di-malformazioni-congenite-e-morte-fetale/ 2013-11-14T14:14:28+00:00 https://www.farmacovigilanzasardegna.it/2013/11/14/reazioni-cutanee-gravi-dovute-agli-inibitori-della-proteina-chinasi/ 2013-11-14T14:16:08+00:00 https://www.farmacovigilanzasardegna.it/2013/11/18/aifa-banca-dati-dei-farmaci-istituzionale/ 2013-11-18T14:03:25+00:00 https://www.farmacovigilanzasardegna.it/2013/11/18/interazione-farmacologica-tra-claritromicina-e-calcio-antagonisti-danno-renale-acuto/ 2013-11-18T14:10:17+00:00 https://www.farmacovigilanzasardegna.it/2013/11/25/ema-i-benefici-dei-contracettivi-ormonali-combinati-continuano-a-superarne-i-rischi/ 2013-11-25T13:48:13+00:00 https://www.farmacovigilanzasardegna.it/2013/11/25/limpatto-della-durata-del-trattamento-sul-tempo-di-insorgenza-delle-reazioni-avverse-a-farmaco/ 2013-11-25T13:51:15+00:00 https://www.farmacovigilanzasardegna.it/2013/11/25/studio-retrospettivo-sullassociazione-tra-esposizione-a-psicofarmaci-e-sindrome-maligna-da-neurolettici/ 2013-11-25T14:01:06+00:00 https://www.farmacovigilanzasardegna.it/2013/12/09/efficacia-comparativa-di-esercizio-fisico-e-terapia-farmacologica-sugli-esiti-di-mortalita-uno-studio-meta-epidemiologico-2/ 2013-12-09T13:44:04+00:00 https://www.farmacovigilanzasardegna.it/2013/12/11/algoritmo-farmacogenetico-vs-algoritmo-clinico-nel-dosaggio-del-warfarin-2/ 2013-12-11T13:30:40+00:00 https://www.farmacovigilanzasardegna.it/2013/12/11/1262/ 2013-12-11T13:41:49+00:00 https://www.farmacovigilanzasardegna.it/2013/12/17/politerapia-e-malnutrizione-2/ 2013-12-17T13:24:14+00:00 https://www.farmacovigilanzasardegna.it/2013/12/17/gli-ingredienti-necessari-per-interventi-efficaci-al-fine-di-migliorare-laderenza-terapeutica/ 2013-12-17T13:28:07+00:00 https://www.farmacovigilanzasardegna.it/2013/12/18/la-farmacogenetica-ha-un-ruolo-nel-dosaggio-degli-antagonisti-della-vitamina-k/ 2013-12-18T13:21:49+00:00 https://www.farmacovigilanzasardegna.it/2014/01/07/linfluenza-della-valutazione-geriatrica-globale-sulla-terapia-farmacologica-nei-pazienti-anziani/ 2014-01-07T11:25:30+00:00 https://www.farmacovigilanzasardegna.it/2014/01/07/uso-di-analgesici-e-rischio-di-cancro-al-rene-una-metanalisi-di-studi-epidemiologici/ 2014-01-07T11:28:40+00:00 https://www.farmacovigilanzasardegna.it/2014/01/13/sospendere-i-farmaci-negli-anziani-un-approccio-evidence-based/ 2014-01-13T11:22:28+00:00 https://www.farmacovigilanzasardegna.it/2014/01/14/aifa-sicurezza-dei-farmaci-segnali-dallarme-per-allopurinolo-ketorolac-e-macrogol/ 2014-01-14T11:19:12+00:00 https://www.farmacovigilanzasardegna.it/2014/01/16/i-trattamenti-farmacologici-per-la-cessazione-del-fumo/ 2014-01-16T11:12:35+00:00 https://www.farmacovigilanzasardegna.it/2014/01/16/le-pagine-del-paziente-pubblicate-su-jama-i-contraccettivi-orali/ 2014-01-16T11:15:51+00:00 https://www.farmacovigilanzasardegna.it/2014/01/20/potenziale-effetto-delle-politerapie-sul-profilo-ematologico-in-pazienti-trattati-con-clozapina/ 2014-01-20T11:09:45+00:00 https://www.farmacovigilanzasardegna.it/2014/01/22/statine-e-funzione-cognitiva/ 2014-01-22T11:06:32+00:00 https://www.farmacovigilanzasardegna.it/2014/01/28/prima-autorizzazione-della-fda-per-lutilizzo-dei-sequenziatori-di-nuova-generazione-a-scopo-clinico/ 2014-01-28T10:59:57+00:00 https://www.farmacovigilanzasardegna.it/2014/01/28/le-riviste-mediche-dovrebbero-smettere-di-pubblicare-le-ricerche-finanziate-dalle-industrie-farmaceutiche/ 2014-01-28T11:02:45+00:00 https://www.farmacovigilanzasardegna.it/2014/01/30/aifa-non-ho-nulla-da-perdere-a-provarlo-cure-miracolose-guida-per-il-paziente/ 2014-01-30T10:52:11+00:00 https://www.farmacovigilanzasardegna.it/2014/01/30/aifa-nota-informativa-importante-sui-contraccettivi-ormonali-combinati/ 2014-01-30T10:54:46+00:00 https://www.farmacovigilanzasardegna.it/2014/02/03/farmaci-e-compromissione-della-capacita-di-guidare-revisione-della-letteratura-2/ 2014-02-03T10:49:03+00:00 https://www.farmacovigilanzasardegna.it/2014/02/06/la-terapia-con-statine-per-la-prevenzione-primaria-delle-patologie-cardiovascolari/ 2014-02-06T10:46:03+00:00 https://www.farmacovigilanzasardegna.it/2014/02/06/dove-sono-le-prove-una-migliore-ricerca-per-una-migliore-assistenza-sanitaria/ 2014-02-06T20:43:13+00:00 https://www.farmacovigilanzasardegna.it/2014/02/12/aifa-luso-dei-farmaci-in-italia-rapporto-osmed/ 2014-02-12T09:37:53+00:00 https://www.farmacovigilanzasardegna.it/2014/02/12/una-replica-sulluso-delle-statine-per-la-prevenzione-primaria/ 2014-02-12T10:40:26+00:00 https://www.farmacovigilanzasardegna.it/2014/02/24/uno-stop-ai-farmaci-ad-alto-dosaggio-di-paracetamolo-dallamericana-food-and-drug-administration-fda-2/ 2014-02-24T10:27:11+00:00 https://www.farmacovigilanzasardegna.it/2014/02/25/automedicazione-con-farmaci-da-banco-e-farmaci-precedentemente-prescritti-2/ 2014-02-25T10:24:06+00:00 https://www.farmacovigilanzasardegna.it/2014/03/05/linee-guida-2014-evidence-based-per-la-gestione-della-pressione-alta-negli-adulti/ 2014-03-05T10:19:53+00:00 https://www.farmacovigilanzasardegna.it/2014/03/06/epatotossicita-correlata-ad-agomelatina-e-altri-antidepressivi-un-approccio-casocontrollo-attraverso-le-informazioni-dei-sistemi-di-farmacovigilanza-portoghese-francese-spagnolo-e-italiano/ 2014-03-06T10:16:45+00:00 https://www.farmacovigilanzasardegna.it/2014/03/10/linee-guida-per-il-trattamento-delle-infezioni-delle-vie-urinarie/ 2014-03-10T10:13:32+00:00 https://www.farmacovigilanzasardegna.it/2014/03/11/aifa-misure-per-la-sicurezza-dei-farmaci-protelososseor-domperidone-diacereina-zolpidem-e-metisergide/ 2014-03-11T10:10:05+00:00 https://www.farmacovigilanzasardegna.it/2014/03/19/un-caso-di-carcinoma-squamocellulare-della-lingua-verificatosi-in-sardegna-in-seguito-a-terapia-con-abatacept-per-il-trattamento-dellartrite-reumatoide/ 2014-03-19T10:04:47+00:00 https://www.farmacovigilanzasardegna.it/2014/03/25/le-opzioni-terapeutiche-per-ridurre-il-rischio-di-ictus-nei-pazienti-affetti-da-fibrillazione-atriale-2/ 2014-03-25T09:56:48+00:00 https://www.farmacovigilanzasardegna.it/2014/03/25/la-fda-approva-luso-della-doxilamina-piridossina-in-gravidanza/ 2014-03-25T10:01:29+00:00 https://www.farmacovigilanzasardegna.it/2014/04/01/valutazione-dellefficacia-del-farmaco-sperimentale-darapladib-in-pazienti-con-malattia-coronarica-cronica/ 2014-04-01T08:55:28+00:00 https://www.farmacovigilanzasardegna.it/2014/04/01/la-rivista-focus-farmacovigilanza-compie-20-anni/ 2014-04-01T18:52:24+00:00 https://www.farmacovigilanzasardegna.it/2014/04/07/effetto-dellassunzione-di-farmaci-ansiolitici-e-ipnoinducenti-sul-rischio-di-mortalita-studio-retrospettivo-di-coorte/ 2014-04-07T09:05:13+00:00 https://www.farmacovigilanzasardegna.it/2014/04/07/il-tribunale-di-torino-rigetta-una-richiesta-di-ordinare-la-somministrazione-di-cellule-staminali-trattate-con-la-c-d-metodologia-di-stamina-foundation/ 2014-04-07T09:14:44+00:00 https://www.farmacovigilanzasardegna.it/2014/04/12/fda-le-modalita-di-approvazione-dei-nuovi-farmaci-negli-stati-uniti/ 2014-04-12T09:30:18+00:00 https://www.farmacovigilanzasardegna.it/2014/04/15/corso-ecm-farmacovigilanza-e-buon-uso-del-farmaco-focus-sugli-anticoagulanti-orali/ 2014-04-15T07:33:57+00:00 https://www.farmacovigilanzasardegna.it/2014/04/16/effetto-delle-prescrizioni-di-ansiolitici-e-ipnotici-sui-rischi-di-mortalita-uno-studio-retrospettivo-di-coorte/ 2014-04-16T09:41:51+00:00 https://www.farmacovigilanzasardegna.it/2014/04/18/la-storia-dei-farmaci-anti-influenzali-oseltamivir-e-zanamivir/ 2014-04-18T09:45:32+00:00 https://www.farmacovigilanzasardegna.it/2014/04/23/profilo-delle-interazioni-farmacologiche-e-farmacocinetica-degli-inibitori-della-pompa-protonica/ 2014-04-23T09:48:51+00:00 https://www.farmacovigilanzasardegna.it/2014/04/24/la-fda-richiede-che-siano-apportate-modifiche-ai-fogli-illustrativi-dei-corticosteroidi-per-segnalare-il-rischio-di-problemi-neurologici-rari-ma-gravi-in-seguito-al-loro-uso-per-via-epidurale-nell/ 2014-04-24T09:51:40+00:00 https://www.farmacovigilanzasardegna.it/2014/05/07/monitoraggio-della-spesa-farmaceutica-regionale-per-lanno-2013-2/ 2014-05-07T16:27:16+00:00 https://www.farmacovigilanzasardegna.it/2014/05/10/1036/ 2014-05-10T16:18:49+00:00 https://www.farmacovigilanzasardegna.it/2014/05/22/statine-e-reazioni-avverse/ 2014-05-22T16:11:31+00:00 https://www.farmacovigilanzasardegna.it/2014/05/26/comunicazione-ema-su-farmaci-che-agiscono-sul-sistema-renina-angiotensina-ras-e-note-informative-importanti-aifa-su-invirase-saquinavir-e-crixivan/ 2014-05-26T16:06:46+00:00 https://www.farmacovigilanzasardegna.it/2014/05/26/reazioni-avverse-a-farmaco-e-la-loro-gestione-clinica-un-punto-di-vista-personale/ 2014-05-26T16:15:44+00:00 https://www.farmacovigilanzasardegna.it/2014/05/28/le-reazioni-avverse-nei-neonati-e-nei-lattanti-e-necessario-un-approccio-tagliato-su-misura-per-la-popolazione/ 2014-05-28T15:45:32+00:00 https://www.farmacovigilanzasardegna.it/2014/05/29/1007/ 2014-05-29T15:33:15+00:00 https://www.farmacovigilanzasardegna.it/2014/05/29/corticosteroidi-e-rischio-di-sanguinamento-gastrointestinale-una-revisione-sistematica-e-meta-analisi/ 2014-05-29T15:38:47+00:00 https://www.farmacovigilanzasardegna.it/2014/06/03/1003/ 2014-06-03T15:12:44+00:00 https://www.farmacovigilanzasardegna.it/2014/06/06/aifa-farmaci-in-pediatria/ 2014-06-06T15:06:36+00:00 https://www.farmacovigilanzasardegna.it/2014/06/10/epatotossicita-indotta-da-metilprednisolone/ 2014-06-10T14:58:29+00:00 https://www.farmacovigilanzasardegna.it/2014/06/17/990/ 2014-06-17T14:53:38+00:00 https://www.farmacovigilanzasardegna.it/2014/06/19/reazioni-avverse-da-uso-di-marijuana/ 2014-06-19T14:38:37+00:00 https://www.farmacovigilanzasardegna.it/2014/06/20/mortalita-ed-eventi-cardiovascolari-associati-alluso-di-azitromicina-tra-i-pazienti-anziani-ospedalizzati-con-polmonite/ 2014-06-20T14:27:46+00:00 https://www.farmacovigilanzasardegna.it/2014/06/23/cambiamento-nelluso-degli-antidepressivi-da-parte-della-popolazione-giovanile-dopo-lavvertimento-della-fda-e-la-copertura-dei-media/ 2014-06-23T14:26:25+00:00 https://www.farmacovigilanzasardegna.it/2014/06/24/uso-di-antidepressivi-in-gravidanza-e-rischio-di-difetti-cardiaci/ 2014-06-24T12:31:16+00:00 https://www.farmacovigilanzasardegna.it/2014/06/25/vitamina-d-e-mortalita/ 2014-06-25T12:23:57+00:00 https://www.farmacovigilanzasardegna.it/2014/06/30/esito-della-sospensione-della-terapia-stabilizzante-nel-disturbo-bipolare-dopo-5-anni-di-eutimia/ 2014-06-30T08:14:59+00:00 https://www.farmacovigilanzasardegna.it/2014/06/30/la-sicurezza-del-farmaco-nellera-digitale/ 2014-06-30T12:01:31+00:00 https://www.farmacovigilanzasardegna.it/2014/07/02/aifa-note-informative-importanti-su-budesonide-ketoprofene-procoralancorlentor-ivabradina-fentanil-cerotto-transdermico-e-revisione-europea-dei-medicinali-contenenti-ibuprofene/ 2014-07-02T10:52:19+00:00 https://www.farmacovigilanzasardegna.it/2014/07/07/il-riso-rosso-fermentato-per-il-trattamento-della-dislipidemia/ 2014-07-07T10:28:56+00:00 https://www.farmacovigilanzasardegna.it/2014/07/09/focus-farmacovigilanza/ 2014-07-09T10:17:35+00:00 https://www.farmacovigilanzasardegna.it/2014/07/14/acqua-sporca-che-cosa-rischiamo-di-buttare-via-con-il-caso-stamina/ 2014-07-14T10:04:04+00:00 https://www.farmacovigilanzasardegna.it/2014/07/18/sono-veramente-necessari-i-trial-clinici-su-vitamina-d-e-mortalita/ 2014-07-18T09:00:24+00:00 https://www.farmacovigilanzasardegna.it/2014/07/18/878-2/ 2014-07-18T18:19:23+00:00 https://www.farmacovigilanzasardegna.it/2014/07/23/617/ 2014-07-23T08:32:26+00:00 https://www.farmacovigilanzasardegna.it/2014/07/23/631/ 2014-07-23T10:44:15+00:00 https://www.farmacovigilanzasardegna.it/2014/07/26/la-rivista-focus-farmacovigilanza-compie-20-anni-2/ 2014-07-26T09:18:33+00:00 https://www.farmacovigilanzasardegna.it/2014/08/05/effetti-avversi-non-cardiovascolari-associati-alla-terapia-con-statine/ 2014-08-05T16:08:16+00:00 https://www.farmacovigilanzasardegna.it/2014/08/05/i-problemi-col-dabigatran/ 2014-08-05T17:10:42+00:00 https://www.farmacovigilanzasardegna.it/2014/08/20/aifa-note-informative-importanti-sui-medicinali-a-base-di-domperidone-la-procedura-di-referral-sul-sistema-renina-angiotensina-ofatumumab-arzerra-e-konakion-ema-comunicazione-sulle-soluzioni-or/ 2014-08-20T15:53:25+00:00 https://www.farmacovigilanzasardegna.it/2014/08/20/una-banca-dati-contro-i-furti-di-medicinali/ 2014-08-20T15:57:38+00:00 https://www.farmacovigilanzasardegna.it/2014/08/25/sodio-potassio-e-pressione-sanguigna/ 2014-08-25T11:03:46+00:00 https://www.farmacovigilanzasardegna.it/2014/08/25/farmaci-associati-ad-eventi-avversi-nei-bambini-e-negli-adolescenti/ 2014-08-25T14:35:51+00:00 https://www.farmacovigilanzasardegna.it/2014/08/25/le-prescrizioni-di-antidepressivi-in-cinque-paesi-europei/ 2014-08-25T15:09:56+00:00 https://www.farmacovigilanzasardegna.it/2014/09/02/la-sicurezza-della-olanzapina-nei-bambini/ 2014-09-02T15:26:18+00:00 https://www.farmacovigilanzasardegna.it/2014/09/03/le-prescrizioni-di-antibiotici-a-pazienti-ambulatoriali-pediatrici-in-5-paesi-europei/ 2014-09-03T05:01:32+00:00 https://www.farmacovigilanzasardegna.it/2014/09/03/linsegnamento-della-farmacovigilanza-il-programma-suggerito-da-oms-e-isop/ 2014-09-03T15:44:22+00:00 https://www.farmacovigilanzasardegna.it/2014/09/10/osteonecrosi-della-mandibola-causata-da-bifosfonati/ 2014-09-10T13:10:39+00:00 https://www.farmacovigilanzasardegna.it/2014/09/12/reazioni-avverse-a-farmaco-e-allattamento/ 2014-09-12T06:36:00+00:00 https://www.farmacovigilanzasardegna.it/2014/09/18/reazioni-avverse-a-farmaco-nei-pazienti-ricoverati-nei-reparti-di-emergenza-unanalisi-dei-costi-diretti/ 2014-09-18T09:22:00+00:00 https://www.farmacovigilanzasardegna.it/2014/09/19/farmacovigilanza-in-pediatria/ 2014-09-19T08:25:18+00:00 https://www.farmacovigilanzasardegna.it/2014/09/25/farmacisti-e-farmacovigilanza-quali-opportunita-per-una-migliore-vigilanza/ 2014-09-25T09:16:00+00:00 https://www.farmacovigilanzasardegna.it/2014/09/26/comunicazione-ema-su-valdoxanthymanax-e-note-informative-importanti-aifa-su-aceclofenac-simulect-basiliximab-prolia-e-xgeva/ 2014-09-26T10:03:00+00:00 https://www.farmacovigilanzasardegna.it/2014/10/01/linee-guida-per-la-diagnosi-e-la-terapia-della-fibrillazione-atriale/ 2014-10-01T11:11:41+00:00 https://www.farmacovigilanzasardegna.it/2014/10/02/corso-ecm-farmacovigilanza-e-buon-uso-del-farmaco-focus-sui-bifosfonati/ 2014-10-02T10:16:12+00:00 https://www.farmacovigilanzasardegna.it/2014/10/10/effetto-delluso-delle-statine-durante-lospedalizzazione-per-emorragia-intracerebrale-sulla-mortalita-e-le-condizioni-di-dimissione/ 2014-10-10T07:00:36+00:00 https://www.farmacovigilanzasardegna.it/2014/10/10/problemi-cardiaci-associati-al-ranelato-di-stronzio/ 2014-10-10T07:19:59+00:00 https://www.farmacovigilanzasardegna.it/2014/10/16/i-farmaci-anti-fattore-di-crescita-vascolare-endoteliale-per-il-trattamento-della-degenerazione-maculare-senile/ 2014-10-16T10:43:55+00:00 https://www.farmacovigilanzasardegna.it/2014/10/17/il-bmj-critica-la-sicurezza-e-luso-di-dabigatran/ 2014-10-17T09:40:23+00:00 https://www.farmacovigilanzasardegna.it/2014/10/28/exenatide-sitagliptin-e-vildagliptin-uso-efficacia-e-sicurezza-per-il-diabete-di-tipo-2-nel-mondo-reale/ 2014-10-28T10:47:04+00:00 https://www.farmacovigilanzasardegna.it/2014/10/31/i-vaccini-possono-interagire-con-il-metabolismo-dei-farmaci/ 2014-10-31T09:15:33+00:00 https://www.farmacovigilanzasardegna.it/2014/10/31/comprendere-le-reazioni-avverse-al-farmaco-negli-anziani-attraverso-le-interazioni-farmacologiche/ 2014-10-31T10:11:35+00:00 https://www.farmacovigilanzasardegna.it/2014/11/06/non-bisogna-utilizzare-di-routine-gli-antipsicotici-per-il-trattamento-di-agitazione-e-aggressivita-nei-pazienti-affetti-da-demenza/ 2014-11-06T09:59:21+00:00 https://www.farmacovigilanzasardegna.it/2014/11/06/aifa-ed-ema-le-principali-notizie-di-ottobre-sulla-sicurezza-dei-farmaci/ 2014-11-06T10:49:15+00:00 https://www.farmacovigilanzasardegna.it/2014/11/11/efficacia-comparativa-e-tollerabilita-delle-terapie-farmacologiche-nel-trattamento-del-disturbo-bipolare/ 2014-11-11T09:44:58+00:00 https://www.farmacovigilanzasardegna.it/2014/11/12/cotrimossazolo-e-morte-improvvisa-nei-pazienti-trattati-con-gli-inibitori-del-sistema-renina-angiotensina/ 2014-11-12T12:00:00+00:00 https://www.farmacovigilanzasardegna.it/2014/11/13/biosimilari-cosa-ce-da-sapere/ 2014-11-13T09:23:04+00:00 https://www.farmacovigilanzasardegna.it/2014/11/14/aifa-richiamo-alla-segnalazione-tempestiva-da-parte-dei-segnalatori/ 2014-11-14T08:43:45+00:00 https://www.farmacovigilanzasardegna.it/2014/11/14/prescrire-la-lista-dei-farmaci-da-evitare/ 2014-11-14T11:33:20+00:00 https://www.farmacovigilanzasardegna.it/2014/11/17/cittadinanzattiva-indagine-civica-sullesperienza-dei-pazienti-rispetto-alluso-dei-farmaci-con-focus-su-farmaci-biologici-e-biosimilari/ 2014-11-17T09:34:40+00:00 https://www.farmacovigilanzasardegna.it/2014/11/17/la-farmacoviglianza-in-italia/ 2014-11-17T10:33:28+00:00 https://www.farmacovigilanzasardegna.it/2014/11/18/senza-regole-non-funzionano/ 2014-11-18T09:06:25+00:00 https://www.farmacovigilanzasardegna.it/2014/11/19/who-antimicrobial-resistance-global-report-on-surveillance-2014/ 2014-11-19T11:25:03+00:00 https://www.farmacovigilanzasardegna.it/2014/11/20/ecdc-annual-report-of-the-european-antimicrobial-resistance-surveillance-network-ears-net-2013/ 2014-11-20T12:02:17+00:00 https://www.farmacovigilanzasardegna.it/2014/12/01/aifa-le-principali-notizie-di-novembre-sulla-sicurezza-dei-farmaci/ 2014-12-01T10:49:26+00:00 https://www.farmacovigilanzasardegna.it/2014/12/05/ema-aifa-aggiornamenti-sul-caso-fluad/ 2014-12-05T13:11:34+00:00 https://www.farmacovigilanzasardegna.it/2014/12/10/la-corte-costituzionale-mette-fine-al-caso-stamina/ 2014-12-10T11:16:32+00:00 https://www.farmacovigilanzasardegna.it/2014/12/10/il-tramadolo-per-il-dolore-non-oncologico/ 2014-12-10T13:36:32+00:00 https://www.farmacovigilanzasardegna.it/2014/12/11/lavvertimento-della-fda-su-antidepressivi-e-rischio-di-suicidio-perche-la-polemica/ 2014-12-11T11:38:08+00:00 https://www.farmacovigilanzasardegna.it/2014/12/11/antidepressivi-10-anni-dopo-il-black-box-warning/ 2014-12-11T12:00:43+00:00 https://www.farmacovigilanzasardegna.it/2014/12/12/aifa-luso-dei-farmaci-in-italia-rapporto-osmed-2013/ 2014-12-12T15:58:12+00:00 https://www.farmacovigilanzasardegna.it/2014/12/15/vaccinovigilanza-in-corso/ 2014-12-15T11:35:38+00:00 https://www.farmacovigilanzasardegna.it/2014/12/15/sperimentazioni-cliniche-i-comitati-etici-devono-proteggere-i-pazienti-da-profitti-e-conflitti/ 2014-12-15T12:44:51+00:00 https://www.farmacovigilanzasardegna.it/2014/12/23/i-%ce%b2-bloccanti-nei-pazienti-con-insufficienza-cardiaca-e-fibrillazione-atriale/ 2014-12-23T11:34:57+00:00 https://www.farmacovigilanzasardegna.it/2014/12/23/le-vaccinazioni-sono-allorigine-dellautismo/ 2014-12-23T13:00:58+00:00 https://www.farmacovigilanzasardegna.it/2014/12/29/acido-valproico-e-decessi-nei-bambini/ 2014-12-29T08:32:04+00:00 https://www.farmacovigilanzasardegna.it/2014/12/30/aifa-le-principali-notizie-di-dicembre-sulla-sicurezza-dei-farmaci/ 2014-12-30T09:39:19+00:00 https://www.farmacovigilanzasardegna.it/2015/01/05/allergia-a-farmaci-le-linee-guida-del-nice/ 2015-01-05T09:34:04+00:00 https://www.farmacovigilanzasardegna.it/2015/01/09/relazione-sullo-stato-sanitario-del-paese-2012-2013/ 2015-01-09T13:00:27+00:00 https://www.farmacovigilanzasardegna.it/2015/01/12/la-collaborazione-per-la-farmacovigilanza-tra-la-food-and-drug-administration-e-lagenzia-europea-per-i-medicinali-obiettivi-e-sfide-comuni/ 2015-01-12T11:15:52+00:00 https://www.farmacovigilanzasardegna.it/2015/01/13/danno-epatico-associato-a-ketoconazolo/ 2015-01-13T10:44:54+00:00 https://www.farmacovigilanzasardegna.it/2015/01/15/specialist-cohort-event-monitoring-scem-un-nuova-metodologia-per-la-farmacovigilanza/ 2015-01-15T09:39:02+00:00 https://www.farmacovigilanzasardegna.it/2015/01/19/infezioni-da-virus-varicella-zoster-in-pazienti-trattati-con-fingolimod-la-valutazione-del-rischio-e-le-raccomandazioni-per-la-gestione/ 2015-01-19T10:44:38+00:00 https://www.farmacovigilanzasardegna.it/2015/01/19/gli-antidepressivi-in-gravidanza/ 2015-01-19T15:47:48+00:00 https://www.farmacovigilanzasardegna.it/2015/01/22/gioco-dazzardo-patologico-ipersessualita-e-shopping-compulsivo-associati-ai-farmaci-agonisti-dei-recettori-della-dopamina/ 2015-01-22T12:00:14+00:00 https://www.farmacovigilanzasardegna.it/2015/01/26/focus-farmacovigilanza-2/ 2015-01-26T08:57:36+00:00 https://www.farmacovigilanzasardegna.it/2015/01/27/trombocitopenia-indotta-da-eparina/ 2015-01-27T09:22:42+00:00 https://www.farmacovigilanzasardegna.it/2015/01/28/farmaci-nella-donna-che-allatta-al-seno-un-approccio-senza-pregiudizi/ 2015-01-28T12:11:38+00:00 https://www.farmacovigilanzasardegna.it/2015/01/29/aifa-le-principali-notizie-di-gennaio-sulla-sicurezza-dei-farmaci/ 2015-01-29T11:53:02+00:00 https://www.farmacovigilanzasardegna.it/2015/02/02/glibenclamide-metformina-e-insulina-per-il-trattamento-del-diabete-gestazionale/ 2015-02-02T11:37:06+00:00 https://www.farmacovigilanzasardegna.it/2015/02/04/possibile-overtreatment-del-diabete-mellito-negli-anziani-a-stretto-controllo-glicemico/ 2015-02-04T11:29:51+00:00 https://www.farmacovigilanzasardegna.it/2015/02/05/luso-dei-farmaci-in-italia-rapporto-osmed-gennaio-settembre-2014/ 2015-02-05T11:12:14+00:00 https://www.farmacovigilanzasardegna.it/2015/02/09/livelli-ottimali-di-pressione-sistolica-tempi-di-intensificazione-della-terapia-e-tempo-di-follow-up-nel-trattamento-dellipertensione/ 2015-02-09T10:26:38+00:00 https://www.farmacovigilanzasardegna.it/2015/02/10/la-diacereina-nel-trattamento-dellosteoartrosi/ 2015-02-10T12:02:00+00:00 https://www.farmacovigilanzasardegna.it/2015/02/18/statine-diabete-di-tipo-2-e-peso-corporeo/ 2015-02-18T10:19:31+00:00 https://www.farmacovigilanzasardegna.it/2015/02/20/oms-piano-globale-dazione-per-la-prevenzione-e-il-controllo-delle-malattie-non-trasmissibili-2013-2020/ 2015-02-20T09:35:26+00:00 https://www.farmacovigilanzasardegna.it/2015/02/24/antibiotici-e-un-peccato-usarli-male-efficaci-se-necessari-dannosi-se-ne-abusi/ 2015-02-24T11:54:41+00:00 https://www.farmacovigilanzasardegna.it/2015/02/27/aifa-le-principali-notizie-di-febbraio-sulla-sicurezza-dei-farmaci/ 2015-02-27T16:18:04+00:00 https://www.farmacovigilanzasardegna.it/2015/03/04/il-trattamento-dellemicrania-acuta-negli-adulti/ 2015-03-04T11:03:35+00:00 https://www.farmacovigilanzasardegna.it/2015/03/05/farmacoterapia-per-il-dolore-neuropatico-negli-adulti/ 2015-03-05T10:33:13+00:00 https://www.farmacovigilanzasardegna.it/2015/03/10/pericolo-di-danno-epatico-indotto-da-farmaco-con-i-nuovi-anticoagulanti-orali/ 2015-03-10T11:59:10+00:00 https://www.farmacovigilanzasardegna.it/2015/03/12/danno-epatico-da-anticoagulanti-orali/ 2015-03-12T07:40:14+00:00 https://www.farmacovigilanzasardegna.it/2015/03/16/focus-farmacovigilanza-3/ 2015-03-16T08:07:11+00:00 https://www.farmacovigilanzasardegna.it/2015/03/17/indagine-conoscitiva-su-origine-e-sviluppo-del-cosiddetto-caso-stamina/ 2015-03-17T11:29:42+00:00 https://www.farmacovigilanzasardegna.it/2015/03/23/la-sicurezza-dei-preparati-di-ferro-per-via-endovenosa/ 2015-03-23T10:08:06+00:00 https://www.farmacovigilanzasardegna.it/2015/03/23/relazione-tra-alert-strutturali-nei-fans-ed-epatotossicita-idiosincratica/ 2015-03-23T12:23:51+00:00 https://www.farmacovigilanzasardegna.it/2015/03/30/la-terapia-sistemica-con-corticosteroidi-per-la-sinusite-acuta/ 2015-03-30T08:32:52+00:00 https://www.farmacovigilanzasardegna.it/2015/03/31/aifa-le-principali-notizie-di-marzo-sulla-sicurezza-dei-farmaci/ 2015-03-31T08:59:42+00:00 https://www.farmacovigilanzasardegna.it/2015/04/08/trend-di-lungo-periodo-nelluso-dei-farmaci-antidiabetici-orali-tra-i-bambini-e-gli-adolescenti-dei-paesi-bassi/ 2015-04-08T10:39:10+00:00 https://www.farmacovigilanzasardegna.it/2015/04/09/epidemiologia-delle-reazioni-avverse-in-europa/ 2015-04-09T10:22:29+00:00 https://www.farmacovigilanzasardegna.it/2015/04/13/un-possibile-effetto-collaterale-benefico-della-metformina/ 2015-04-13T06:52:29+00:00 https://www.farmacovigilanzasardegna.it/2015/04/14/standardizzazione-del-fenotipo-per-lnsufficienza-renale-causata-da-farmaci/ 2015-04-14T07:56:50+00:00 https://www.farmacovigilanzasardegna.it/2015/04/15/interazioni-farmaco-malattia-e-farmaco-farmaco/ 2015-04-15T07:40:16+00:00 https://www.farmacovigilanzasardegna.it/2015/04/30/aifa-le-principali-notizie-di-aprile-sulla-sicurezza-dei-farmaci/ 2015-04-30T10:08:29+00:00 https://www.farmacovigilanzasardegna.it/2015/04/30/corso-ecm-del-centro-regionale-di-farmacovigilanza/ 2015-04-30T10:29:56+00:00 https://www.farmacovigilanzasardegna.it/2015/05/06/focus-farmacovigilanza-4/ 2015-05-06T11:54:54+00:00 https://www.farmacovigilanzasardegna.it/2015/05/07/incidenza-e-natura-delle-reazioni-avverse-agli-antibiotici-usati-per-la-profilassi-dellendocardite/ 2015-05-07T10:12:19+00:00 https://www.farmacovigilanzasardegna.it/2015/05/13/alcol-e-problemi-correlati/ 2015-05-13T10:37:25+00:00 https://www.farmacovigilanzasardegna.it/2015/05/14/cosa-puo-insegnarci-il-data-mining-che-non-sappiamo-gia-sulla-sicurezza-dei-triptani/ 2015-05-14T10:25:23+00:00 https://www.farmacovigilanzasardegna.it/2015/05/20/monitoraggio-della-sicurezza-dei-medicinali-lema-inizia-lo-screening-della-letteratura-medica-per-400-gruppi-di-sostanze-attive/ 2015-05-20T16:36:12+00:00 https://www.farmacovigilanzasardegna.it/2015/05/21/la-profilassi-con-aspirina-nella-prevenzione-cardiovascolare/ 2015-05-21T11:05:04+00:00 https://www.farmacovigilanzasardegna.it/2015/05/27/tiroide-prevenzione-e-terapia/ 2015-05-27T10:10:05+00:00 https://www.farmacovigilanzasardegna.it/2015/05/28/effetti-a-lungo-termine-del-litio-su-funzionalita-renale-tiroidea-e-paratiroidea/ 2015-05-28T08:53:09+00:00 https://www.farmacovigilanzasardegna.it/2015/06/01/aifa-le-principali-notizie-di-maggio-sulla-sicurezza-dei-farmaci/ 2015-06-01T11:16:04+00:00 https://www.farmacovigilanzasardegna.it/2015/06/03/gli-steroidi-orali-per-la-radicolopatia-acuta-dovuta-ad-ernia-del-disco-lombare/ 2015-06-03T10:49:06+00:00 https://www.farmacovigilanzasardegna.it/2015/06/04/efficacia-e-sicurezza-comparativa-degli-agenti-antipertensivi-in-adulti-con-diabete-e-malattie-renali/ 2015-06-04T09:35:02+00:00 https://www.farmacovigilanzasardegna.it/2015/06/08/uso-di-antidepressivi-in-gravidanza-e-rischio-di-ipertensione-polmonare-persistente-del-neonato-pphn/ 2015-06-08T08:45:36+00:00 https://www.farmacovigilanzasardegna.it/2015/06/09/vareniclina-e-rischio-di-disturbi-psichiatrici-comportamenti-suicidari-incidenti-stradali/ 2015-06-09T10:13:51+00:00 https://www.farmacovigilanzasardegna.it/2015/06/15/cosmetovigilanza/ 2015-06-15T11:27:32+00:00 https://www.farmacovigilanzasardegna.it/2015/06/16/rischio-comparativo-di-sanguinamento-gastrointestinale-con-dabigatran-rivaroxaban-e-warfarin/ 2015-06-16T10:37:01+00:00 https://www.farmacovigilanzasardegna.it/2015/06/23/gli-aggiornamenti-della-normativa-in-materia-di-farmacovigilanza/ 2015-06-23T11:09:07+00:00 https://www.farmacovigilanzasardegna.it/2015/06/24/caffeina/ 2015-06-24T10:34:17+00:00 https://www.farmacovigilanzasardegna.it/2015/06/30/aifa-le-principali-notizie-di-giugno-sulla-sicurezza-dei-farmaci/ 2015-06-30T15:45:50+00:00 https://www.farmacovigilanzasardegna.it/2015/07/03/sindrome-serotoninergica/ 2015-07-03T10:45:19+00:00 https://www.farmacovigilanzasardegna.it/2015/07/04/farmacovigilanza-per-leta-pediatrica/ 2015-07-04T10:32:11+00:00 https://www.farmacovigilanzasardegna.it/2015/07/08/mortalita-associata-alla-digossina/ 2015-07-08T09:48:01+00:00 https://www.farmacovigilanzasardegna.it/2015/07/09/uso-degli-inibitori-di-pompa-protonica-e-rischio-di-infarto-miocardico-nella-popolazione-generale/ 2015-07-09T07:53:29+00:00 https://www.farmacovigilanzasardegna.it/2015/07/15/terapia-antibiotica-vs-appendicectomia/ 2015-07-15T08:56:51+00:00 https://www.farmacovigilanzasardegna.it/2015/07/16/sistemi-di-segnalazione-spontanea-delle-reazioni-avverse-a-farmaco-adr-e-fascicoli-sanitari/ 2015-07-16T10:03:44+00:00 https://www.farmacovigilanzasardegna.it/2015/07/22/profilassi-della-cefalea-emicranica/ 2015-07-22T11:38:31+00:00 https://www.farmacovigilanzasardegna.it/2015/07/29/luso-dei-farmaci-in-italia-rapporto-osmed-2014/ 2015-07-29T11:16:13+00:00 https://www.farmacovigilanzasardegna.it/2015/07/30/aifa-le-principali-notizie-di-luglio-sulla-sicurezza-dei-farmaci/ 2015-07-30T10:46:43+00:00 https://www.farmacovigilanzasardegna.it/2015/08/06/il-litio-per-losteoartrite/ 2015-08-06T10:44:36+00:00 https://www.farmacovigilanzasardegna.it/2015/08/06/farmacogenetica-del-prolungamento-dellintervallo-qt-farmaco-indotto/ 2015-08-06T11:11:19+00:00 https://www.farmacovigilanzasardegna.it/2015/08/10/inibitori-selettivi-della-ricaptazione-della-serotonina-ssri-in-gravidanza-e-malformazioni-congenite-del-neonato/ 2015-08-10T11:25:22+00:00 https://www.farmacovigilanzasardegna.it/2015/08/12/farmacogenomica-e-farmaci-per-il-sistema-cardiovascolare/ 2015-08-12T10:45:17+00:00 https://www.farmacovigilanzasardegna.it/2015/08/18/focus-farmacovigilanza-5/ 2015-08-18T11:01:08+00:00 https://www.farmacovigilanzasardegna.it/2015/08/20/comunicazione-della-fda-sulla-sicurezza-dei-farmaci-antinfiammatori-non-steroidei-fans/ 2015-08-20T08:09:58+00:00 https://www.farmacovigilanzasardegna.it/2015/08/31/la-sindrome-da-farmacovigilanza/ 2015-08-31T09:51:25+00:00 https://www.farmacovigilanzasardegna.it/2015/08/31/aifa-le-principali-notizie-di-agosto-sulla-sicurezza-dei-farmaci/ 2015-08-31T10:48:39+00:00 https://www.farmacovigilanzasardegna.it/2015/08/31/ecm-farmacovigilanza-e-buon-uso-del-farmaco-focus-sugli-anticoagulanti-orali/ 2015-08-31T10:57:23+00:00 https://www.farmacovigilanzasardegna.it/2015/09/09/confronto-tra-nuovi-anticoagulanti-orali-e-antagonisti-della-vitamina-k/ 2015-09-09T07:57:52+00:00 https://www.farmacovigilanzasardegna.it/2015/09/10/lo-sapevi-anche-tu-puoi-segnalare-gli-effetti-indesiderati-di-un-medicinale/ 2015-09-10T07:16:29+00:00 https://www.farmacovigilanzasardegna.it/2015/09/10/gestione-della-terapia-anticoagulante-nei-pazienti-con-sanguinamento-gastrointestinale-acuto/ 2015-09-10T09:36:29+00:00 https://www.farmacovigilanzasardegna.it/2015/09/14/la-mini-guida-di-onda-sulla-contraccezione/ 2015-09-14T07:08:30+00:00 https://www.farmacovigilanzasardegna.it/2015/09/16/linee-guida-per-il-reporting-di-revisioni-sistematiche-e-meta-analisi-il-prisma-statement/ 2015-09-16T08:13:47+00:00 https://www.farmacovigilanzasardegna.it/2015/09/21/caffeina-e-progressione-della-malattia-di-parkinson/ 2015-09-21T14:27:18+00:00 https://www.farmacovigilanzasardegna.it/2015/09/30/aifa-le-principali-notizie-di-settembre-sulla-sicurezza-dei-farmaci/ 2015-09-30T06:00:21+00:00 https://www.farmacovigilanzasardegna.it/2015/09/30/corso-ecm-del-centro-regionale-di-farmacovigilanza-2/ 2015-09-30T13:31:07+00:00 https://www.farmacovigilanzasardegna.it/2015/09/30/ecm-farmacovigilanza-e-buon-uso-del-farmaco-focus-sugli-anticoagulanti-orali-2/ 2015-09-30T14:41:55+00:00 https://www.farmacovigilanzasardegna.it/2015/10/06/inibitori-di-pompa-protonica/ 2015-10-06T15:18:49+00:00 https://www.farmacovigilanzasardegna.it/2015/10/07/laspirina-come-agente-neoadiuvante-durante-la-chemioradioterapia-preoperatoria-per-cancro-del-retto/ 2015-10-07T14:56:14+00:00 https://www.farmacovigilanzasardegna.it/2015/10/13/il-rapporto-2015-sugli-antibiotici/ 2015-10-13T13:41:09+00:00 https://www.farmacovigilanzasardegna.it/2015/10/14/il-litio-nel-trattamento-del-disturbo-bipolare-i-in-eta-pediatrica/ 2015-10-14T09:02:47+00:00 https://www.farmacovigilanzasardegna.it/2015/10/20/nuovi-approcci-terapeutici-per-la-prevenzione-e-il-trattamento-dellemicrania/ 2015-10-20T06:42:00+00:00 https://www.farmacovigilanzasardegna.it/2015/10/20/health-at-a-glance-2015/ 2015-10-20T14:08:59+00:00 https://www.farmacovigilanzasardegna.it/2015/10/29/emicrania-mestruale/ 2015-10-29T12:00:19+00:00 https://www.farmacovigilanzasardegna.it/2015/10/31/aifa-le-principali-notizie-di-ottobre-sulla-sicurezza-dei-farmaci/ 2015-10-31T10:41:55+00:00 https://www.farmacovigilanzasardegna.it/2015/11/03/reazioni-avverse-da-integratori-alimentari/ 2015-11-03T09:29:39+00:00 https://www.farmacovigilanzasardegna.it/2015/11/04/correzione-dello-stile-di-vita-e-metformina-migliorano-la-sensibilita-allinsulina-2/ 2015-11-04T12:17:58+00:00 https://www.farmacovigilanzasardegna.it/2015/11/05/sindrome-di-kounis/ 2015-11-05T13:33:03+00:00 https://www.farmacovigilanzasardegna.it/2015/11/06/reazioni-avverse-da-paracetamolo/ 2015-11-06T15:18:20+00:00 https://www.farmacovigilanzasardegna.it/2015/11/09/fans-e-sanguinamento-gastrointestinale/ 2015-11-09T16:48:27+00:00 https://www.farmacovigilanzasardegna.it/2015/11/10/type-2-diabetes-genetics-beta/ 2015-11-10T08:18:28+00:00 https://www.farmacovigilanzasardegna.it/2015/11/10/focus-farmacovigilanza-6/ 2015-11-10T10:25:51+00:00 https://www.farmacovigilanzasardegna.it/2015/11/11/la-prevenzione-delle-reazioni-avverse-da-farmaco-in-pazienti-anziani-ospedalizzati/ 2015-11-11T09:08:16+00:00 https://www.farmacovigilanzasardegna.it/2015/11/12/oseltamivir-per-linfluenza-nei-bambini/ 2015-11-12T10:06:12+00:00 https://www.farmacovigilanzasardegna.it/2015/11/13/la-copertura-vaccinale-degli-operatori-sanitari-contro-linfluenza-stagionale/ 2015-11-13T10:36:32+00:00 https://www.farmacovigilanzasardegna.it/2015/11/16/world-antibiotic-awareness-week/ 2015-11-16T08:22:59+00:00 https://www.farmacovigilanzasardegna.it/2015/11/17/la-resistenza-agli-antimicrobici-lidra-in-mezzo-a-noi/ 2015-11-17T08:20:39+00:00 https://www.farmacovigilanzasardegna.it/2015/11/18/european-antibiotic-awareness-day-2015/ 2015-11-18T07:11:25+00:00 https://www.farmacovigilanzasardegna.it/2015/11/18/antibiotici-e-asma/ 2015-11-18T07:31:30+00:00 https://www.farmacovigilanzasardegna.it/2015/11/19/uso-di-antibiotici-e-rischio-di-diabete-di-tipo-2/ 2015-11-19T07:34:57+00:00 https://www.farmacovigilanzasardegna.it/2015/11/19/utilizzo-degli-antibiotici-in-pediatria/ 2015-11-19T10:37:12+00:00 https://www.farmacovigilanzasardegna.it/2015/11/25/uno-studio-farmacovigilanza-sul-primo-episodio-di-psicosi/ 2015-11-25T10:38:11+00:00 https://www.farmacovigilanzasardegna.it/2015/11/26/la-societa-americana-di-geriatria-ha-pubblicato-laggiornamento-2015-dei-criteri-di-beers/ 2015-11-26T11:42:23+00:00 https://www.farmacovigilanzasardegna.it/2015/11/30/aifa-le-principali-notizie-di-novembre-sulla-sicurezza-dei-farmaci-2/ 2015-11-30T12:03:38+00:00 https://www.farmacovigilanzasardegna.it/2015/12/04/farmaci-cardiovascolari-generici-e-di-marca/ 2015-12-04T10:36:13+00:00 https://www.farmacovigilanzasardegna.it/2015/12/07/farmaci-essenziali-in-un-paese-ad-alto-reddito-essenziali-per-chi/ 2015-12-07T12:29:21+00:00 https://www.farmacovigilanzasardegna.it/2015/12/09/genere-nelle-malattie-cardiovascolari-impatto-sulle-manifestazioni-cliniche-gestione-e-risultati/ 2015-12-09T12:25:24+00:00 https://www.farmacovigilanzasardegna.it/2015/12/10/medicinali-equivalenti-qualita-sicurezza-ed-efficacia-un-viaggio-allo-scoperta-delle-regole-per-autorizzare-un-medicinale-equivalente-generico/ 2015-12-10T11:10:55+00:00 https://www.farmacovigilanzasardegna.it/2015/12/15/sicurezza-del-vaccino-antinfluenzale-vivo-attenuato-nei-giovani-con-allergia-alluovo/ 2015-12-15T10:53:20+00:00 https://www.farmacovigilanzasardegna.it/2015/12/16/associazione-tra-linsorgenza-di-reazioni-avverse-a-farmaco-adr-ed-uso-off-label-dei-farmaci-in-una-popolazione-adulta/ 2015-12-16T09:16:21+00:00 https://www.farmacovigilanzasardegna.it/2015/12/17/cosmetovigilanza-2/ 2015-12-17T07:45:39+00:00 https://www.farmacovigilanzasardegna.it/2015/12/18/antidepressivi-di-seconda-generazione-versus-terapie-cognitive-comportamentali-nel-trattamento-della-depressione/ 2015-12-18T22:40:56+00:00 https://www.farmacovigilanzasardegna.it/2015/12/21/uso-pregravidico-di-contraccettivi-orali-e-peso-del-neonato-alla-nascita/ 2015-12-21T10:40:58+00:00 https://www.farmacovigilanzasardegna.it/2015/12/22/genere-salute-e-gli-obiettivi-dello-sviluppo-sostenibile/ 2015-12-22T11:49:42+00:00 https://www.farmacovigilanzasardegna.it/2015/12/23/agenzia-italiana-del-farmaco-monitoraggio-della-spesa-farmaceutica-regionale/ 2015-12-23T13:47:04+00:00 https://www.farmacovigilanzasardegna.it/2015/12/28/ibuprofene-versus-fosfomicina/ 2015-12-28T10:10:10+00:00 https://www.farmacovigilanzasardegna.it/2015/12/28/abbassamento-della-pressione-sanguigna-per-la-prevenzione-di-malattie-cardiovascolari-e-morte/ 2015-12-28T12:28:46+00:00 https://www.farmacovigilanzasardegna.it/2015/12/29/politerapia-appropriata-e-medicina-di-sicurezza-quando-molti-non-sono-troppi/ 2015-12-29T09:08:35+00:00 https://www.farmacovigilanzasardegna.it/2015/12/29/la-vaccinazione-antinfluenzale-in-gravidanza/ 2015-12-29T16:21:04+00:00 https://www.farmacovigilanzasardegna.it/2015/12/30/aifa-le-principali-notizie-di-dicembre-sulla-sicurezza-dei-farmaci-2/ 2015-12-30T08:55:18+00:00 https://www.farmacovigilanzasardegna.it/2019/08/23/le-interazioni-tra-farmaci-nelle-unita-di-terapia-intensiva/ 2020-07-20T08:55:35+00:00 https://www.farmacovigilanzasardegna.it/2019/08/23/ema-pubblicato-laggiornamento-del-qppv/ 2020-07-20T08:55:35+00:00 https://www.farmacovigilanzasardegna.it/2019/08/30/lutilizzo-di-biomarkers-nelle-sperimentazioni-cliniche-pre-marketing-per-una-migliore-valutazione-del-profilo-di-sicurezza-dei-farmaci-candidati/ 2020-07-20T08:55:35+00:00 https://www.farmacovigilanzasardegna.it/2019/08/30/cosa-succede-dopo-la-mia-segnalazione-di-sospetta-reazione-avversa-a-farmaco/ 2020-07-20T08:55:35+00:00 https://www.farmacovigilanzasardegna.it/2019/08/30/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-agosto-2019/ 2020-07-20T08:55:35+00:00 https://www.farmacovigilanzasardegna.it/2019/06/28/possibile-associazione-tra-contraccettivi-orali-e-rischio-di-suicidio/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/06/21/interazioni-tra-farmaci-e-fitoterapici/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/06/28/brevi-cicli-di-corticosteroidi-orali-quanto-possono-far-male/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/05/report-sulla-sicurezza-del-vaccino-ricombinante-per-lherpes-zoster-shingrix/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/05/identificare-e-de-prescrivere-i-farmaci-potenzialmente-inutili-nei-pazienti-con-insufficienza-renale/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/06/28/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-giugno-2019/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/19/modesta-associazione-tra-finasteride-dutasteride-e-diabete-mellito-tipo-ii/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/12/i-farmaci-biosimilari-spiegati-ai-pazienti/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/12/gli-eccipienti-inattivi-dei-farmaci-orali/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/19/rischio-beneficio-di-vedolizumab-nel-trattamento-di-crohn-e-colite-ulcerosa/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/26/luso-dei-farmaci-in-italia-rapporto-osmed-2018/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/08/02/aifa-report-sulle-segnalazioni-di-eventi-avversi-da-farmaci-biosimilari/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/26/la-prevenzione-della-cardiotossicita-nella-terapia-del-carcinoma-mammario/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/07/31/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-luglio-2019/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/08/02/aifa-rapporto-sui-vaccini-del-2018/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/08/09/perdita-di-mineralizzazione-ossea-e-osteoporosi-indotta-da-farmaco/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/08/09/meningite-asettica-indotta-da-farmaco/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/08/16/profilo-di-sicurezza-degli-ipoglicemizzanti-orali-focus-sulle-gliptine/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/08/16/la-farmacovigilanza-in-ambito-oncologico/ 2020-07-20T08:55:53+00:00 https://www.farmacovigilanzasardegna.it/2019/06/21/qualcuno-ancora-crede-che-il-vaccino-morbillo-parotite-rosolia-sia-causa-di-autismo/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/04/19/le-uova-e-il-colesterolo-un-dibattito-sempre-aperto/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/04/19/il-diabete-insulino-dipendente-indotto-da-un-inibitore-del-check-point/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/04/16/nota-informativa-importante-antibiotici-chinolonici-e-fluorochinolonici-per-uso-sistemico-e-inalatorio/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/04/26/le-statine-aderenza-e-mortalita-nei-pazienti-con-aterosclerosi/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/03/sicurezza-e-efficacia-dei-derivati-della-cannabis-nelle-patologie-neurologiche/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/04/26/settimana-mondiale-per-limmunizzazione-24-30-aprile-2019/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/03/luso-della-tamsulosina-oltre-lipertrofia-prostatica-benigna/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/10/le-complicanze-emergenti-delle-terapie-biologiche-nella-sclerosi-multipla/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/04/30/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-aprile-2019/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/10/il-contributo-della-cannabis-sullincidenza-di-episodi-psicotici-in-europa/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/10/il-ruolo-del-farmacista-per-la-sicurezza-dei-pazienti-geriatrici/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/17/la-gestione-del-dolore-acuto-nei-pazienti-intolleranti-al-lattosio/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/24/caso-clinico-uomo-di-62-anni-con-fibrillazione-atriale-depressione-ansia-prolungamento-intervallo-qt/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/24/ipoglicemia-malattie-cardiovascolari-e-mortalita-nel-diabete-epidemiologia-patogenesi-e-gestione/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/17/alzheimer-e-integratori-alimentari-il-rischio-di-ignorare-levidenza-scientifica/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/24/la-sicurezza-dei-farmaci-antipsicotici-focus-sulla-clozapina/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/27/farmacovigilanza-con-e-per-il-cittadino-i-farmaci-equivalenti/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/27/io-equivalgo/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/06/07/alemtuzumab-ed-emorragia-intracranica/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/31/reazioni-di-fotosensibilita-farmaco-indotte-un-update-sui-farmaci-coinvolti-sulla-prevenzione-e-gestione-delle-reazioni-avverse/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/31/come-ridurre-al-minimo-luso-inappropriato-dei-farmaci/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/06/07/le-reazioni-avverse-cutanee-gravi/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/31/montelukast-nei-bambini-asmatici-rischio-di-eventi-neuropsichiatrici/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/05/31/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-maggio-2019/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/06/14/luso-eccessivo-di-antibiotici-nellarco-della-vita-e-associato-a-malattie-cardiovascolari/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/06/14/eventi-avversi-2-0-le-raccomandazioni-serio/ 2020-07-20T08:55:54+00:00 https://www.farmacovigilanzasardegna.it/2019/02/15/valutazione-e-gestione-dellallergia-alla-penicillina/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/04/05/psicosi-nei-pazienti-con-disturbo-da-deficit-di-attenzione-e-iperattivita-adhd-trattati-con-metilfenidato-e-amfetamine/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/04/05/esposizione-prenatale-ad-acido-valproico-e-rischio-di-adhd/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/04/05/effetti-dellesposizione-prenatale-alla-terapia-antiretrovirale-con-efavirenz/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/08/sistema-nazionale-di-sorveglianza-sentinella-dellantibiotico-resistenza-ar-iss-protocollo-2019/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/22/la-farmacovigilanza-nella-popolazione-pediatrica/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/01/la-terapia-con-statine-nelle-persone-anziane/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/22/luso-del-litio-in-gravidanza/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/28/aur-derm-crema-prodotto-privo-di-autorizzazione-alla-commercializzazione/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/28/rischio-di-malformazioni-congenite-associate-a-farmaci-antiepilettici/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/28/aifa-notizie-di-febbraio-2019-sulla-sicurezza-dei-farmaci/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/08/rischio-di-infezioni-associate-a-tocilizumab-nellartrite-reumatoide/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/15/luso-del-fluconazolo-per-via-orale-in-gravidanza/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/22/la-vitamina-d-per-la-prevenzione-del-cancro-e-delle-malattie-cardiovascolari/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/15/ripensare-antibiotici/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/15/inibitori-della-pompa-protonica-e-rischio-di-malattia-renale-acuta-e-cronica/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/15/osteoporosi-denosumab-necrosi-della-mandibola-e-procedure-odontoiatriche/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/01/aifa-le-notizie-di-gennaio-2019-sulla-sicurezza-dei-farmaci/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/29/sistemi-di-farmacovigilanza-nellera-delle-informazioni/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/22/abatacept-come-prima-terapia-biologica-per-lartrite-reumatoide-e-il-rischio-di-sviluppare-il-cancro/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/01/31/benzodiazepine-e-rischio-polmonite-un-dibattito-aperto/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/22/effetto-nocebo-quando-anche-il-placebo-provoca-reazioni-avverse/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/04/12/depressione-antidepressivi-e-rischio-di-fibrillazione-atriale-non-valvolare/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/03/29/aifa-notizie-di-marzo-2019-sulla-sicurezza-dei-farmaci/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/02/08/aspirina-nella-prevenzione-primaria-del-rischio-cardiovascolare-analisi-di-efficacia-e-sicurezza/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2019/04/12/luso-degli-antibiotici-in-italia-rapporto-nazionale-anno-2017/ 2020-07-20T08:55:55+00:00 https://www.farmacovigilanzasardegna.it/2018/11/23/biosimilari-2/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/12/04/vigierbe/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/09/29/aifa-le-notizie-di-settembre-sulla-sicurezza-dei-farmaci/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/04/ibuprofene-versus-paracetamolo/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/12/11/infliximab-e-biosimilare-a-confronto/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/08/terapia-endocrina-adiuvante-a-lungo-termine/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/09/antidepressivi-e-dipendenza/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/11/antibiotici/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2019/01/18/european-medicines-agency-gli-highlights-del-2018/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/16/la-farmacovigilanza-per-la-promozione-del-buon-uso-del-farmaco-e-la-sicurezza-del-paziente/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/18/calcio-antagonisti-e-rischio-di-cancro-polmonare/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/20/atezolizumab-nab-paclitaxel/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2019/01/16/aifa-le-notizie-di-settembre-dicembre-2018-sulla-sicurezza-dei-farmaci/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2019/01/18/siamo-davvero-allergici-alla-penicillina/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2019/01/25/vaccinarsi-una-scelta-combattuta-gli-obiettivi-2019-delloms/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/22/ace-inibitori-e-rischio-di-cancro-al-polmone/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2019/01/25/xxvii-seminario-nazionale-la-valutazione-delluso-e-della-sicurezza-dei-farmaci-esperienze-in-italia/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/10/23/nuovi-anticoagulanti-orali-nao/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/09/18/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale-7/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/09/19/statine-per-la-prevenzione-primaria-di-eventi-cardiovascolari-e-mortalita/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/09/20/piperacillina-e-tazobactam-vs-meropenem/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2019/01/25/i-farmaci-oppiacei-possono-peggiorare-lesito-di-un-infarto-miocardico-acuto/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/12/05/farmacovigilanza-con-e-per-il-cittadino/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/09/27/i-livelli-essenziali-di-assistenza-lea/ 2020-07-20T08:55:56+00:00 https://www.farmacovigilanzasardegna.it/2018/08/02/disturbo-da-deficit-di-attenzione-e-iperattivita/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/03/inibitori-della-pompa-protonica-e-rischio-di-demenza/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/04/cannabis-ad-uso-medico/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/03/integratori-a-base-i-riso-rosso-fermentato/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/05/morbillo/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/06/efficacia-e-tollarabilita-di-21-antidepressivi-a-confronto/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/07/farmaci-estate/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/05/i-farmaci-biosimilari-nellunione-europea/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/08/inibitori-della-pompa-protonica-e-rischio-di-danno-renale-acuto/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/06/biosimilari/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/09/asma-laba-e-o-glucocorticoidi-inalatori/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/10/sulfaniluree-come-farmaci-di-seconda-linea-nel-diabete-di-tipo-2/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/10/statine-e-miopatia/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/11/laspirina-nella-prevenzione-primaria/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/20/nao-vs-aspirina/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/10/laspirina-nella-prevenzione-primaria-2/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/21/agenti-stimolanti-leritropoiesi-esa/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/12/laspirina-nella-prevenzione-primaria-1/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/07/23/rivaroxaban-versus-aspirina/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/09/17/aspirina-nuove-prospettive-per-la-cura-dellalzheimer/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/22/la-profilassi-con-emicizumab-nellemofilia-a/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/23/nao-versus-warfarin/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/07/25/carbetocina-termostabile-versus-ossitocina/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/27/biosimilari-e-originator-a-confronto/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/07/31/aifa-le-principali-notizie-di-luglio-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/27/infliximab-biosimilare/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/31/aifa-le-principali-notizie-di-agosto-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/08/01/issalute/ 2020-07-20T08:56:10+00:00 https://www.farmacovigilanzasardegna.it/2018/06/19/statine-e-reazioni-avverse-muscolo-scheletriche/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/16/paracetamolo-nella-prevenzione-del-danno-renale-acuto/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/21/bollettini-sulle-ondate-di-calore/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/17/luso-dei-farmaci-in-italia/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/31/aifa-le-principali-notizie-di-maggio-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/21/vareniclina-bupropione-e-cerotti-alla-nicotina/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/01/aimovig/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/17/ipp-nei-pazienti-con-cirrosi/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/26/supplementazione-di-vitamina-d-in-gravidanza/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/28/vitamina-b6-e-neuropatia/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/18/modernizzare-la-formazione-in-farmacovigilanza-per-gli-operatori-sanitari/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/26/glucocorticoidi-e-rischio-di-sanguinamento-dellulcera-peptica/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/29/canakinumab/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/18/warfarin-e-rischio-di-sanguinamento/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/27/contraccettivi-ormonali-combinati-coc/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/19/reazioni-avverse-a-farmaco-in-eta-pediatrica/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/28/aifa-le-principali-notizie-di-giugno-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/11/sulfametoxazolo-e-trimetoprim-in-gravidanza/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/15/elbasvir-grazoprevir/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/23/laspirina-nella-prevenzione-di-eventi-cardiovascolari-e-cancro-colonrettale/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/12/eudravigilance-il-data-base-europeo-delle-segnalazioni-di-sospette-reazioni-avverse/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/15/inibitori-del-sglt2-analoghi-del-glp-1-inibitori-della-dpp-4/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/05/inibitori-selettivi-della-ricaptazione-della-serotonina/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/10/rapporto-vaccini-2017/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/13/nuovi-anticoagulanti-orali/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/16/gli-antagonisti-dopaminergici-negli-episodi-acuti-di-disturbo-dellumore/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/11/la-misura-della-performance-dei-ssr-vi-edizione-2018/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/14/depressione-da-farmaci/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/16/gli-effetti-indesiderabili-da-cosmetici-e-la-cosmetovigilanza/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/14/clozapina-ed-eventi-avversi/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/11/alteplasi-versus-aspirina/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/06/18/farmaci-anticolinergici-e-rischio-di-demenza/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/05/21/trombocitopenia-da-eparina/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/07/12/vaccino-anti-hpv-2/ 2020-07-20T08:56:11+00:00 https://www.farmacovigilanzasardegna.it/2018/03/06/supplementazione-di-acidi-grassi-omega-3-e-rischio-cardiovascolare/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/05/03/reazioni-avverse-ad-antidolorifici/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/09/acido-soppressori-o-antibiotici-nel-primo-semestre-di-vita/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/05/03/oppiacei-per-il-trattamento-del-dolore-cronico-in-italia/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/10/le-vaccinazioni-pediatriche-e-degli-adulti-i-piu-recenti-aggiornamenti/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/07/prestazioni-in-eta-scolare-di-bambini-esposti-al-valproato-in-utero/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/10/antibiotici-chinoloni-e-fluorochinoloni/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/05/08/ema-2017-annual-report/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/10/canagliflozin-versus-altre-classi-di-farmaci-antidiabetici/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/12/budesonide-per-la-displasia-broncopolmonare-bpd/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/05/14/una-bufala-ci-seppellira/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/13/anticoagulanti-nella-popolazione-anziana-con-fibrillazione-atriale-e-malattia-renale-cronica/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/11/corticosteroidi-inalatori-lama-e-o-laba/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/05/10/carenza-di-vitamina-d-e-prognosi-di-bpco-a-lungo-termine/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/14/impatto-della-terapia-ormonale-sostitutiva-sul-cuore/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/05/10/febuxostat-vs-allopurinolo/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/12/terapia-smart-corticosteroidi-inalatori-laba/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/19/uso-di-fluorochinoloni-e-rischio-di-aneurisma-o-dissezione-dellaorta/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/12/relazione-al-parlamento-su-alcol-e-problemi-alcol-correlati/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/23/asenapina-nella-gestione-di-impulsivita-e-aggressivita/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/16/beta-bloccanti-in-gravidanza/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/27/secondo-position-paper-sui-farmaci-biosimilari/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/03/30/aifa-le-principali-notizie-di-marzo-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/18/valutazione-delle-misure-di-minimizzazione-del-rischio/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/03/danno-epatico-acuto-da-antidepressivi/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/23/vaccineswork-i-vaccini-funzionano/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/04/aspirina-vs-rivaroxaban/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/05/tripla-terapia-inalatoria-extrafine-versus-terapia-broncodilatatoria-doppia/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/04/30/aifa-le-principali-notizie-di-aprile-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:12+00:00 https://www.farmacovigilanzasardegna.it/2018/02/15/sovradosaggio-di-paracetamolo-e-danno-epatico/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/02/20/position-statement-sulluso-di-farmaci-da-parte-della-donna-che-allatta-al-seno/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/03/01/dottore-ma-e-vero-che/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/02/28/aifa-le-principali-notizie-di-febbraio-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/03/01/terapia-addizionale-con-rifampicina-nelle-batteriemie-da-stafilococco-aureo/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/03/02/la-vaccinazione-anti-influenzale-nei-gruppi-a-rischio/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/03/03/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale-6/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/03/05/effetti-dei-gastroprotettori-nella-prevenzione-e-nel-trattamento-dellulcera-peptica/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/02/14/trimetoprim-per-le-infezioni-urinarie-e-rischio-di-adr/ 2020-07-20T08:56:13+00:00 https://www.farmacovigilanzasardegna.it/2018/01/30/global-antimicrobial-resistance-surveillance-system-glass-report-early-implementation-2016-17/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/03/tripla-terapia-antipiastrinica-versus-doppia-terapia/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/31/aifa-le-principali-notizie-di-gennaio-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/02/i-farmaci-orfani-nellunione-europea/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/05/corticosteroidi-per-inalazione-e-rischio-di-fratture/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/01/working-for-every-patient-in-europe/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/19/immunogenicita-e-sicurezza-del-vaccino-meningococcico-b-multicomponente-4cmenb-in-bambini-e-adolescenti/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/01/from-lab-to-patient/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/01/keeping-medicines-safe/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/08/rischio-di-ricaduta-dopo-linterruzione-di-antidepressivi-per-disturbi-dansia-e-ossessivi-compulsivi-e-da-stress-post-traumatico/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/05/interventi-per-frenare-le-prescrizioni-ospedaliere-di-ipp/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/05/farmaci-per-uso-umano/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/09/potenziali-interazioni-farmacologiche-dei-nuovi-anticoagulanti-orali/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/05/danno-epatico-farmaco-indotto-e-reazioni-averse-cutanee-gravi/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/10/comorbidita-politerapia-e-interazioni-farmacologiche/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/08/nao-warfarin-o-nessun-anticoagulante-orale/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2017/12/31/aifa-le-principali-notizie-di-dicembre-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/15/chi-non-fuma-sta-una-favola/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2017/12/29/aripiprazolo-e-rischio-di-aborto-spontaneo/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/20/teriparatide-versus-risedronato/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/13/le-passioni-di-velo-dalle-prostaglandine-allecofarmacovigilanza/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/22/acido-folico-e-vitamine-prima-e-o-durante-la-gravidanza/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2017/12/27/romosozumab-versus-teriparatide/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/12/uso-di-farmaci-psicotropi-ed-oppioidi-in-gravidanza-e-rischio-di-sindrome-da-astinenza-nei-neonati/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2017/12/30/inibitori-del-sistema-renina-angiotensina-e-rischio-fratture-2/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/23/multimorbidita-politerapia-e-richio-di-reazioni-avverse-a-farmaco-nella-broncopneumopatia-cronica-ostruttiva/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/02/13/sicurezza-dei-vaccini-anti-papillomavirus-umano/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2018/01/29/una-reazione-avversa-grave-a-5-fluorouracile-topico/ 2020-07-20T08:56:28+00:00 https://www.farmacovigilanzasardegna.it/2017/11/07/farmaci-per-lasma-cronica-perche-e-come-ridurli/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/09/prescrizione-di-nao-e-rischio-di-sanguinamento/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/05/somministrazione-precoce-di-acido-tranexamico-in-donne-con-emorragia-post-partum/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/15/global-handwashing-day/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/14/world-antibiotic-awareness-week-13-19-november-2017/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/17/world-antibiotic-awareness-week-13-19-novembre-2017/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/16/world-antibiotic-awareness-week-13-19-novembre-2017-2/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/17/okkio-alla-salute/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/19/global-tuberculosis-report-2017/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/04/faq-influenza-e-vaccinazione-antinfluenzale/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/21/piano-nazionale-di-contrasto-dellantimicrobico-resistenza-pncar-2017-2020/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/02/campagna-vaccinale-contro-linfluenza/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/06/16-rapporto-nazionale-sulla-sperimentazione-clinica-dei-medicinali-in-italia/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/07/associazione-tra-luso-di-farmaci-antitrombotici-ed-ematuria/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/18/nuovi-anticoagulanti-orali-e-warfarin-a-confronto/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/23/le-segnalazioni-dei-pazienti-in-farmacovigilanza/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/22/la-sorveglianza-postmarketing-dei-vaccini-in-italia/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/19/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale-5/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/24/inibitori-selettivi-della-ricaptazione-della-serotonina-e-prolungamento-dellintervallo-qt/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/29/il-valore-della-farmacovigilanza-dal-caso-talidomide-alla-sicurezza-dei-farmaci/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/30/aifa-le-principali-notizie-di-novembre-sulla-sicurezza-dei-farmaci-4/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/25/tossicita-gastrointestinale-con-inibitori-selettivi-della-cox-2-eo-fans-convenzionali/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/28/doppia-terapia-antitrombotica-con-dabigatran-vs-tripla-terapia-con-warfarin/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/13/il-morbillo-nellunione-europea/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/30/enoxaparina-in-gravidanza/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/22/gli-antidepressivi-in-oncologia/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/31/aifa-le-principali-notizie-di-ottobre-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/14/liraglutide-orale/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/18/ace-inibitori-e-statine-in-adolescenti-con-diabete-di-tipo-1/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/11/06/ipp-e-rischio-di-cancro-gastrico-dopo-trattamento-per-helicobacter-pylori/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/23/aspirina-a-basso-dosaggio-come-trattamento-adiuvante-delle-ulcere-venose-delle-gambe/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/10/16/inibitori-della-pompa-protonica-e-rischio-di-morte/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/12/01/nuovi-anticoagulanti-orali-nao-e-rischio-di-sanguinamento-maggiore/ 2020-07-20T08:56:29+00:00 https://www.farmacovigilanzasardegna.it/2017/08/30/terapia-ormonale-nei-pazienti-anziani-con-ipotiroidismo-subclinico/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/04/il-sistema-ram-report-reazioni-avverse-dei-medicinali/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/26/anziani-le-condizioni-di-salute-in-italia-e-nellunione-europea/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/03/la-vaccinovigilanza-in-italia/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/05/vaccini-la-miglior-difesa-per-il-nostro-futuro/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/28/statine-a-basso-dosaggio-versus-statine-a-basso-dosaggioarmolipid-plus/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/07/benzodiazepine-e-rischio-di-mortalita-per-tutte-le-cause-negli-adulti/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/05/decreto-vaccini/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/09/la-segnalazione-dei-pazienti-nellunione-europea/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/29/effetti-del-farmaco-sperimentale-anacetrapib-su-pazienti-con-coronaropatia/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/08/openwho/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/30/sicurezza-dei-farmaci-approvati-con-procedura-accelerata/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/05/segnalare-le-reazioni-avverse-a-farmaco/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/10/fans-e-rischio-di-infarto-miocardico-acuto-nel-mondo-reale/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/10/terapia-con-statine-ad-alta-intensita-e-mortalita-in-pazienti-con-aterosclerosi/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/30/aifa-le-principali-notizie-di-settembre-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/06/antibiotici-ed-eventi-avversi/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/11/consumo-di-antimicrobici-e-sviluppo-di-antibiotico-resistenza/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/10/04/inibitori-del-sistema-renina-angiotensina-e-rischio-fratture/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/07/clozapina-versus-antipsicotici-iniettabili-a-rilascio-prolungato/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/10/05/supplementazione-di-vitamina-d-per-prevenire-lesacerbazione-dellasma/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/21/degludec-vs-glargine/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/13/profilo-di-sicurezza-degli-antistaminici-anti-h1-in-pediatria/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/29/influenza-le-raccomandazioni-per-la-stagione-2017-2018/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/07/27/esitazione-vaccinale-e-morbillo/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/19/efficacia-e-sicurezza-di-evolocumab/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/08/21/degludec-vs-glargine-2/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/09/19/terapia-ormonale-sostitutiva-e-mortalita/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/07/31/aifa-le-principali-notizie-di-luglio-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:30+00:00 https://www.farmacovigilanzasardegna.it/2017/07/13/ridinilazolo-vs-vancomicina/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/12/lalendronato-protegge-dal-rischio-di-frattura-allanca/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/17/l-cisteina-in-compresse-per-smettere-di-fumare/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/18/supplementazione-di-vitamina-d-ad-alto-dosaggio-versus-dose-standard/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/24/luso-dei-farmaci-in-italia-rapporto-osmed-2016/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/24/farmaciestate/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/27/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale-4/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/26/strategie-di-prescrizione-degli-antibiotici-ed-esiti-avversi-nelle-infezioni-del-tratto-respiratorio-inferiore/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/07/10/uso-di-antidepressivi-in-gravidanza-e-rischio-di-sindrome-da-deficit-di-attenzione-e-iperattivita-nel-bambino/ 2020-07-20T08:56:31+00:00 https://www.farmacovigilanzasardegna.it/2017/04/24/vaccino-anti-hpv/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/14/vaccinazioni-obbligatorie-da-zero-a-16-anni/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/10/reazioni-averse-alle-statine-effetto-nocebo/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/04/26/aifa-la-vaccinovigilanza-in-italia-ruolo-ed-obiettivi/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/13/i-vaccini-e-le-vaccinazioni/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/04/29/uso-di-antibiotici-in-gravidanza/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/19/il-nuovo-eudravigilance/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/09/vaccini-una-discussione-oltre-le-ideologie/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/04/29/incidenza-degli-enterobatteri-resistenti-ai-carbapenemi/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/15/supplementazione-di-vitamina-d3calcio-e-incidenza-del-cancro-in-donne-in-postmenopausa/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/20/vaccinazioni-le-ragioni-dellobbligo/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/04/24/world-immunization-week/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/20/uso-di-litio-in-gravidanza-a-rischio-di-malformazioni-cardiache/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/31/who-world-no-tobacco-day/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/21/la-cascata-prescrittiva-rivisitata/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/22/associazione-tra-uso-di-alcol-e-insorgenza-di-malattie-cardiovascolari/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/22/trattamenti-a-base-di-incretine-e-mortalita-in-pazienti-con-diabete-di-tipo-2/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/27/solfato-ferroso-o-complesso-di-polisaccaridi-di-ferro/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/17/io-combatto-il-cancro/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/04/29/aifa-le-principali-notizie-di-aprile-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/31/aifa-le-principali-notizie-di-maggio-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/05/rapporto-sulla-sorveglianza-post-marketing-dei-vaccini/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/28/aifa-le-principali-notizie-di-giugno-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/05/combattere-lantibiotico-resistenza-e-nelle-tue-mani/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/05/valutazioni-economiche-degli-interventi-di-prevenzione-delle-infezioni-ospedaliere/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/07/03/aspirina-versus-placebo-in-gravidanze-ad-alto-rischio-di-gestosi/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/06/il-decalogo-della-societa-italiana-di-pediatria/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/06/levoluzione-della-mortalita-per-causa-le-prime-25-cause-di-morte/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/07/i-farmaci-essenziali-2017/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/06/epatite-acuta-indotta-da-aloe-vera/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/07/06/antibiotici-per-piccoli-ascessi-cutanei/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/08/consapevolezza-conoscenza-e-percezione-dei-biosimilari/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/06/08/mangiare-piu-sano-per-la-prevenzione-delle-malattie-cardiovascolari/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/05/08/i-biosimilari-nellunione-europea/ 2020-07-20T08:56:46+00:00 https://www.farmacovigilanzasardegna.it/2017/03/09/uso-di-alcol-e-rischio-di-demenza/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/01/luso-di-statine-nella-prevenzione-primaria-di-eventi-cardiovascolari-negli-adulti/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/13/uso-di-cannabis-e-rischio-di-disturbi-psichiatrici/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/16/vaccinazioni-e-assistenza-sanitaria-in-siria/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/17/il-codice-di-condotta-advance/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/07/euro-health-consumer-index-2016/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/20/dabigatran-vs-warfarin-e-rischio-di-fratture-ostoporotiche/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/22/depression-and-other-common-mental-disorders-global-health-estimates/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/21/rivaroxaban-o-aspirina-per-il-trattamento-esteso-del-tromboembolismo-venoso/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/27/nuovi-anticoagulanti-orali-a-dosaggio-ridotto-versus-warfarin/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/03/vaccinazioni-stato-dellarte-falsi-miti-e-prospettive-il-ruolo-chiave-della-prevenzione/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/08/effetti-vascolari-dellobestatina-in-soggetti-magri-e-obesi/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/28/workshop-misurare-limpatto-delle-attivita-di-farmacovigilanza/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/22/seconda-giornata-nazionale-dedicata-alla-salute-della-donna/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/09/supplementazione-di-acido-folico-per-la-prevenzione-dei-difetti-del-tubo-neurale/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/13/uso-di-antidepressivi-in-gravidanza/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/24/il-vaccino-anti-influenzale-20172018/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/23/morbillo-e-rosolia-nasce-moronet/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/29/attacchi-di-panico-farmaco-indotti/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/14/the-european-union-summary-report-on-antimicrobial-resistance-in-zoonotic-and-indicator-bacteria-from-humans-animals-and-food-in-2015/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/29/aifa-le-principali-notizie-di-marzo-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/10/reazioni-avverse-a-rituximab/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/03/the-global-patient-safety-challenge-on-medication-safety/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/15/uso-regolare-di-aspirina-e-cancro-letale-alla-prostata/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/01/31/aifa-le-principali-notizie-di-gennaio-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/03/eta-di-insorgenza-della-menopausa-e-rischio-di-fratture/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/28/aifa-le-principali-notizie-di-febbraio-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/01/30/15-rapporto-nazionale-sulla-sperimentazione-clinica-dei-medicinali-in-italia-2016/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/05/disturbo-ossessivo-compulsivo-avanzamenti-nella-diagnosi-e-nel-trattamento/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/23/prevenzione-ed-educazione-al-corretto-uso-degli-antibiotici-per-sconfiggere-lantibioticoresistenza/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/04/18/uso-a-breve-termine-di-corticosteroidi-per-via-orale-e-danni-correlati/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/06/uso-del-placebo-per-estendere-gli-effetti-della-terapia-antidolorifica/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/03/08/farmaci-di-origine-vegetale-in-cardiologia/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2017/02/02/rivaroxaban-e-dabigatran-a-confronto/ 2020-07-20T08:56:47+00:00 https://www.farmacovigilanzasardegna.it/2016/10/31/aifa-le-principali-notizie-di-ottobre-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/02/linfluenza-201617/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/25/nuovi-antivirali-ad-azione-diretta-per-lepatite-c/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/17/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale-3/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/23/ebola-il-vaccino-fornisce-alta-protezione-contro-la-malattia/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/08/eu-wide-awareness-campaign/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/04/carenza-di-vitamina-d-e-mal-di-testa-cronico-negli-uomini/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/31/aifa-le-principali-notizie-di-dicembre-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/09/zika-virus/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/14/world-antibiotic-awareness-week-2016/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/27/profilo-di-sicurezza-degli-anticoagulanti-orali-diretti-o-nuovi-anticoagulanti-orali/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/05/il-valore-della-segnalazione-dei-pazienti-al-sistema-di-farmacovigilanza/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/05/sicurezza-ed-efficacia-del-diclofenac-a-basso-dosaggio-per-il-trattamento-del-dolore-acuto/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/10/31/corso-ecm-vaccini-e-vaccinovigilanza/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/18/world-antiobiotic-awareness-week-2016-campaign-toolkit/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/09/ritiro-post-marketing-di-462-prodotti-medicinali-a-causa-di-reazioni-avverse-al-farmaco/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/19/depression-lets-talk/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/28/rapporto-sullinfluenza/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/21/reazioni-avverse-cutanee-a-farmaco/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/06/effetti-cardiovascolari-del-liraglutide-in-pazienti-con-diabete-di-tipo-2/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/10/uso-di-benzodiazepine-e-rischio-di-ictus-nei-malati-di-alzheimer/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/16/resistenza-agli-antibiotici-equivoci-e-idee-sbagliate-diffusi-tra-la-popolazione-mondiale/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/13/livelli-essenziali-di-assistenza-lea/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/30/aifa-le-principali-notizie-di-novembre-sulla-sicurezza-dei-farmaci-3/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/06/olumiant-riduce-linfiammazione-e-altri-sintomi/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/28/problemi-del-linguaggio-scolastici-o-motorii-in-bambini-nati-da-madri-esposte-agli-inibitori-selettivi-della-ricaptazione-della-serotonina-durante-la-gravidanza/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/13/associazione-tra-contraccezione-ormonale-e-depressione/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/12/15/effetto-dellevolocumab-sulla-progressione-della-malattia-coronarica-in-pazienti-trattati-con-statine/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/23/piano-nazionale-prevenzione-vaccinale-2017-2019/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/24/effetto-dellidrocortisone-sullo-sviluppo-dello-shock-settico/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/11/23/polmonite-acquisita-in-comunita-prima-e-dopo-la-prescrizione-di-inibitori-della-pompa-protonica/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2017/01/23/meningite-cosa-ce-da-sapere/ 2020-07-20T08:56:48+00:00 https://www.farmacovigilanzasardegna.it/2016/08/25/diagnosi-e-gestione-delle-reazioni-di-ipersensibilita-ai-mezzi-di-contrasto-nella-pratica-clinica/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/21/antibiotico-resistenza/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/24/il-sotto-utilizzo-dei-farmaci-equivalenti-in-italia/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/12/interpretazione-delle-prove-di-efficacia-e-sicurezza-della-terapia-con-statine/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/28/global-report-on-access-to-hepatitis-c-treatment-focus-on-overcoming-barriers/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/08/23/la-lisdexamfetamina-nel-trattamento-del-disturbo-da-alimentazione-incontrollata-negli-adulti/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/17/uso-di-benzodiazepine-e-rischio-di-demenza-incidente-o-di-declino-cognitivo-uno-studio-prospettico-basato-sulla-popolazione/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/13/aducanumab-riduce-le-placche-del-peptide-beta-amiloide-a%ce%b2-nella-malattia-di-alzheimer/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/08/30/doppia-terapia-antipiastrinica-prolungata-vs-breve-dopo-angioplastica-coronarica-in-pazienti-con-o-senza-arteriopatia-periferica/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/29/rischio-di-mortalita-con-luso-concomitante-di-tamoxifene-e-inibitori-selettivi-della-ricaptazione-della-serotonina/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/09/fnomceo-e-biblioteca-virtuale-ebsco/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/30/aifa-le-principali-notizie-di-settembre-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/09/sfide-per-la-prevenzione-secondaria-dopo-infarto-miocardico-acuto/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/15/litio-passato-presente-e-futuro/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/12/il-nice-affronta-il-problema-del-calo-della-copertura-vaccinale/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/03/fans-e-rischio-di-insufficienza-cardiaca-in-quattro-paesi-europei/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/05/sindrome-di-kounis-da-antibiotici/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/31/lettera-aperta-del-presidente-ricciardi-al-procuratore-della-repubblica-pignatone/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/31/morbillo-e-vaccinazione-contro-il-morbillo/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/19/la-resistenza-agli-antibiotici/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/10/la-prescrizione-di-oppioidi-per-il-dolore-cronico-negli-stati-uniti/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/28/calendario-vaccinale-per-la-vita/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/12/effetti-dellaspirina-su-rischio-e-gravita-di-recidiva-precoce-dopo-attacco-ischemico-transitorio-e-ictus-ischemico/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/08/31/aifa-sicurezza-dei-farmaci-agosto/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/08/30/la-vaccinazione-contro-lhpv-negli-stati-uniti-e-in-cina/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/10/14/associazione-tra-rifiuto-del-vaccino-e-malattie-prevenibili/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/09/27/debellato-il-morbillo-nel-continente-americano/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/08/29/stime-della-copertura-globale-del-vaccino-anti-papillomavirus-umano-per-regione-e-livello-di-reddito/ 2020-07-20T08:56:59+00:00 https://www.farmacovigilanzasardegna.it/2016/07/28/world-hepatitis-day/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/05/31/aifa-le-principali-notizie-di-maggio-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/27/luso-dei-farmaci-in-italia-rapporto-osmed-2015/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/05/30/guida-farmaci-estate/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/30/aifa-le-principali-notizie-di-giugno-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/06/ruolo-e-carico-mondiale-dellinfluenza-nelle-ospedalizzazioni-pediatriche-per-cause-respiratorie/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/06/sicurezza-cardiovascolare-del-metilfenidato-in-bambini-e-adolescenti-con-sindrome-da-deficit-di-attenzione-e-iperattivita-adhd/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/08/08/effetti-del-liraglutide-sulla-stabilita-clinica-in-pazienti-con-insufficienza-cardiaca-avanzata-e-ridotta-frazione-di-eiezione/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/08/mortalita-negli-anziani-trattati-con-antidepressivi-e-antipsicotici-classificati-con-rischio-di-aritmia-e-torsione-di-punta/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/11/affrontare-lantibiotico-resistenza-a-livello-mondiale/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/09/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/08/09/domperidone-e-rischio-di-tachiaritmia-ventricolare-e-morte-cardiaca-improvvisa-nei-malati-di-parkinson/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/20/documento-sui-vaccini/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/10/farmaci-lasa-look-alikesound-alike/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/08/16/uso-di-pioglitazone-e-rischio-di-cancro-alla-vescica-in-pazienti-con-diabete-di-tipo-2/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/07/diabete-di-tipo-1-negli-adulti-diagnosi-e-trattamento-ng17/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/08/17/effetto-della-abaloparatide-vs-placebo-sulle-nuove-fratture-vertebrali-in-donne-in-postmenopausa-con-osteoporosi/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/21/ipoglicemizzanti-a-confronto-in-pazienti-con-diabete-di-tipo-2/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/22/differenze-di-genere-nella-prescrizione-di-antibiotici-nelle-cure-primarie/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/15/la-sindrome-da-deficit-di-attenzione-e-iperattivita-negli-adolescenti/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/08/18/iperuricemia-da-farmaci-e-gotta/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/29/un-batterio-commensale-umano-produce-un-antibiotico-che-inibisce-la-colonizzazione-di-un-patogeno/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/08/22/relazione-della-commissione/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/14/epatite-c-obiettivi-mondiali-e-realta-nazionali/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/25/nuovi-anticoagulanti-orali-vs-warfarin/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/05/23/statine-e-vaccino-antinfluenzale/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/26/antipsicotici-di-prima-e-seconda-generazione-nel-trattamento-della-schizofrenia/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/05/24/statine-e-vaccino-antinfluenzale-negli-anziani/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/05/25/eventi-avversi-di-lunga-durata-dopo-la-vaccinazione-con-cervarix/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/16/concept-paper-sui-farmaci-biosimilari/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/30/aifa-le-principali-notizie-di-luglio-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/05/26/prevalenza-dellhpv-dopo-lavvio-del-programma-di-vaccinazione-negli-stati-uniti/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/20/inibitori-della-pompa-protonica-e-rischio-di-ipomagnesiemia/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/21/rischio-di-insufficienza-cardiaca-ospedalizzata-nei-nuovi-utilizzatori-di-saxagliptin-sitagliptin-e-altri-ipoglicemizzanti/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/07/29/monitoraggio-della-spesa-farmaceutica-nazionale-e-regionale-2/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/06/22/uso-di-statine-e-rischio-di-glioma/ 2020-07-20T08:57:00+00:00 https://www.farmacovigilanzasardegna.it/2016/04/28/carta-italiana-per-la-promozione-delle-vaccinazioni/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/02/29/aifa-le-principali-notizie-di-febbraio-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/22/monitoraggio-della-spesa-farmaceutica/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/29/nuovi-giocatori-in-campo-per-il-trattamento-preventivo-dellemicrania/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/29/il-contributo-della-farmacocinetica-alla-farmacovigilanza/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/29/inibitori-di-pompa-protonica-e-gastroenterite/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/30/aifa-le-principali-notizie-di-aprile-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/31/aifa-le-principali-notizie-di-marzo-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/07/beat-diabetes-on-world-health-day-7-april-2016/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/07/effetti-della-somministrazione-precoce-di-idrocortisone-a-basso-dosaggio-sulla-sopravvivenza-senza-displasia-broncopolmonare-nei-neonati-estremamente-pretermine/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/11/aliskiren-eo-enalapril/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/05/02/contraccettivi-orali-combinati-a-basso-dosaggio-di-estrogeni-e-rischio-di-embolia-polmonare-ictus-e-infarto-miocardico/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/08/il-vaccino-antinfluenzale-per-la-stagione-20162017/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/12/le-vaccinazioni-in-italia/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/09/sito-web-httpwww-farmacovigilanzasif-org/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/05/04/rischio-di-cancro-alla-prostata-nei-pazienti-trattati-con-aspirina-a-basso-dosaggio/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/05/09/le-nuove-linee-guida-per-una-corretta-alimentazione-mettono-gli-zuccheri-aggiunti-nel-mirino/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/14/sicurezza-ed-efficacia-di-amg-334-per-la-prevenzione-dellemicrania-episodica/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/05/05/the-2015-2020-dietary-guidelines-for-americans/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/14/amiodarone-lidocaina-o-placebo-nellarresto-cardiaco-extraospedaliero/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/15/inibitori-della-dipeptidil-peptidasi-4-dpp-4-e-rischio-di-insufficienza-cardiaca-nel-diabete-di-tipo-2/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/22/sicurezza-ed-efficacia-neuropsichiatrica-di-vareniclina-bupropione-e-cerotto-alla-nicotina-nei-fumatori-con-e-senza-disturbi-psichiatrici/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/05/10/luso-di-oppioidi-nel-mondo-e-le-barriere-di-accesso/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/17/incretine-e-rischio-di-cancro-al-pancreas/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/18/consumo-di-caffe-e-rischio-di-cancro/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/18/una-risposta-proattiva-allabuso-di-prescrizioni-di-oppioidi/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/23/world-immunization-week-2016-close-the-immunization-gap/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/26/il-vaccino-rvsv-zebov-contro-il-virus-ebola/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/04/27/american-society-of-clinical-oncology-statement/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/03/21/supplementazione-materna-gestazionale-di-vitamina-d-e-salute-ossea-del-neonato/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/05/17/laspirina-per-la-prevenzione-del-cancro/ 2020-07-20T08:57:01+00:00 https://www.farmacovigilanzasardegna.it/2016/02/26/asma-trattamento-farmacologico-prima-durante-e-dopo-la-gravidanza/ 2020-07-20T08:57:02+00:00 https://www.farmacovigilanzasardegna.it/2016/02/11/decorso-risultato-e-gestione-delle-reazioni-avverse-a-farmaco-associate-alluso-di-metformina/ 2020-07-20T08:57:02+00:00 https://www.farmacovigilanzasardegna.it/2016/02/15/suicidalita-e-aggressivita-durante-il-trattamento-antidepressivo/ 2020-07-20T08:57:02+00:00 https://www.farmacovigilanzasardegna.it/2016/02/16/le-sfide-etiche-delluso-compassionevole-2/ 2020-07-20T08:57:02+00:00 https://www.farmacovigilanzasardegna.it/2016/02/25/enquete-relative-aux-specialites-pharmaceutiques-contenant-du-valproate-de-sodium-rapport/ 2020-07-20T08:57:02+00:00 https://www.farmacovigilanzasardegna.it/2016/01/29/aifa-le-principali-notizie-di-gennaio-sulla-sicurezza-dei-farmaci-2/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/02/04/guida-alla-valutazione-delle-reazioni-avverse-osservabili-dopo-vaccinazione/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/02/05/uppsala-monitoring-centre-annual-report-2015/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/02/04/world-cancer-day-2016/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/02/08/uso-di-inibitori-di-pompa-protonica-e-rischio-di-malattia-renale-cronica/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/02/09/prac-strategy-on-measuring-the-impact-of-pharmacovigilance-activities/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/02/10/uso-di-fluconazolo-orale-durante-la-gravidanza/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/01/29/laifa-sui-farmaci-per-lepatite-c/ 2020-07-20T08:57:13+00:00 https://www.farmacovigilanzasardegna.it/2016/01/12/farmaci-generici-e-biosilimilari-uso-e-spesa/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/13/ricoveri-demergenza-per-emorragia-maggiore-associata-alluso-di-anticoagulanti-orali-diretti/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/14/profilo-di-sicurezza-ed-efficacia-della-terapia-con-infliximab/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/14/efficacia-sicurezza-e-tollerabilita-dellaumento-della-farmacoterapia-con-aripiprazolo-nel-trattamento-della-depressione-resistente-in-tarda-eta/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/15/domperidone-e-rischio-di-morte-cardiaca-improvvisa/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/20/ageing-debate-the-issues/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/21/rischio-cardiovascolare-associato-alluso-della-claritromicina/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/22/14-rapporto-nazionale-sulla-sperimentazione-clinica-dei-medicinali-in-italia-2015/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/25/uso-materno-di-contraccettivi-orali-e-rischio-di-difetti-alla-nascita/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2016/01/28/luso-dei-farmaci-in-italia-rapporto-osmed-gennaio-settembre-2015/ 2020-07-20T08:57:14+00:00 https://www.farmacovigilanzasardegna.it/2020/01/10/lamotrigina-e-rischio-di-linfoistiocitosi-adr-rara-ma-fatale/ 2020-09-14T08:31:51+00:00 https://www.farmacovigilanzasardegna.it/2020/01/03/rischio-di-tumori-cutanei-in-soggetti-che-utilizzano-ace-inibitori-bloccanti-del-recettore-dellangiotensina-e-diuretici-tiazidici/ 2020-09-14T08:31:52+00:00 https://www.farmacovigilanzasardegna.it/2020/01/03/prodotti-a-base-di-cannabidiolo-cbd-possono-davvero-essere-assunti-in-sicurezza/ 2020-09-14T08:31:52+00:00 https://www.farmacovigilanzasardegna.it/2020/01/10/utilizzo-potenziale-del-nilotinib-nel-morbo-di-parkinson-effetti-sulla-sicurezza-tollerabilita-e-biomarker/ 2020-09-14T08:31:52+00:00 https://www.farmacovigilanzasardegna.it/2019/12/06/rischi-ed-eventi-avversi-collegati-allautomedicazione/ 2020-09-14T08:31:53+00:00 https://www.farmacovigilanzasardegna.it/2019/12/06/giornata-mondiale-per-laids-la-comunita-fa-la-differenza/ 2020-09-14T08:31:53+00:00 https://www.farmacovigilanzasardegna.it/2019/12/13/vitamina-d-le-nuove-modalita-prescrittive-nella-scheda-aifa/ 2020-09-14T08:31:53+00:00 https://www.farmacovigilanzasardegna.it/2019/12/20/le-frontiere-della-scienza-medica-riprodurre-la-tossicita-epatica-dei-farmaci-sin-dalle-prime-fasi-di-sviluppo/ 2020-09-14T08:31:53+00:00 https://www.farmacovigilanzasardegna.it/2019/12/13/metformina-e-rischio-di-acidosi-lattica/ 2020-09-14T08:31:53+00:00 https://www.farmacovigilanzasardegna.it/2019/12/20/aifa-monitoraggio-e-consumi-spesa-biosimilari-2019/ 2020-09-14T08:31:53+00:00 https://www.farmacovigilanzasardegna.it/2019/11/29/rapporto-nazionale-aifa-luso-degli-antibiotici-in-italia-nel-2018/ 2020-09-14T08:31:54+00:00 https://www.farmacovigilanzasardegna.it/2019/11/29/efficacia-della-triplice-terapia-elexacaftor-tezacaftor-ivacaftor-nella-fibrosi-cistica-genotipo-a-funzione-minima/ 2020-09-14T08:31:54+00:00 https://www.farmacovigilanzasardegna.it/2019/11/29/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-novembre-2019/ 2020-09-14T08:31:54+00:00 https://www.farmacovigilanzasardegna.it/2019/11/15/rischio-di-mortalita-correlata-alluso-di-oppioidi/ 2020-09-14T08:31:55+00:00 https://www.farmacovigilanzasardegna.it/2019/11/19/aifa-modalita-di-somministrazione-del-medicinale-vancomicina-polvere-per-concentrato-per-soluzione-per-infusione/ 2020-09-14T08:31:55+00:00 https://www.farmacovigilanzasardegna.it/2019/11/22/il-ruolo-della-farmacovigilanza-nella-valutazione-della-pancreatite-acuta-farmaco-indotta/ 2020-09-14T08:31:55+00:00 https://www.farmacovigilanzasardegna.it/2019/11/22/15011/ 2020-09-14T08:31:55+00:00 https://www.farmacovigilanzasardegna.it/2019/11/28/comunicato-aifa-la-segnalazione-dei-farmaci-biologici-e-biosimilari/ 2020-09-14T08:31:55+00:00 https://www.farmacovigilanzasardegna.it/2019/11/08/farmaci-usati-per-il-trattamento-della-malattia-di-alzheimer-e-rischio-di-mortalita-e-ospedalizzazione/ 2020-09-14T08:31:56+00:00 https://www.farmacovigilanzasardegna.it/2019/11/08/farmaci-biosimilari-valore-e-vantaggi/ 2020-09-14T08:31:56+00:00 https://www.farmacovigilanzasardegna.it/2019/11/15/farmaci-e-suicidio-quali-aumentano-e-quali-riducono-il-rischio-di-suicidalita/ 2020-09-14T08:31:56+00:00 https://www.farmacovigilanzasardegna.it/2019/10/25/oms-giornata-mondiale-per-la-sicurezza-della-terapia/ 2020-09-14T08:31:57+00:00 https://www.farmacovigilanzasardegna.it/2019/11/01/il-primo-vaccino-contro-lebola/ 2020-09-14T08:31:57+00:00 https://www.farmacovigilanzasardegna.it/2019/11/01/medicinali-equivalenti-qualita-sicurezza-ed-efficacia/ 2020-09-14T08:31:57+00:00 https://www.farmacovigilanzasardegna.it/2019/10/31/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-ottobre-2019/ 2020-09-14T08:31:57+00:00 https://www.farmacovigilanzasardegna.it/2019/10/11/naturale-non-significa-sicuro-la-sicurezza-dei-prodotti-di-bellezza/ 2020-09-14T08:31:58+00:00 https://www.farmacovigilanzasardegna.it/2019/10/18/luso-di-benzodiazepine-e-oppioidi-nella-broncopneumopatia-cronico-ostruttiva-bpco/ 2020-09-14T08:31:58+00:00 https://www.farmacovigilanzasardegna.it/2019/10/25/farmaci-antitumorali-orali-valutazione-della-sicurezza-e-modificazioni-del-dosaggio-nella-pratica-clinica/ 2020-09-14T08:31:58+00:00 https://www.farmacovigilanzasardegna.it/2019/10/18/ministero-della-salute-guida-alluso-sicuro-dei-farmaci/ 2020-09-14T08:31:58+00:00 https://www.farmacovigilanzasardegna.it/2019/09/27/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-settembre-2019/ 2020-09-14T08:31:59+00:00 https://www.farmacovigilanzasardegna.it/2019/10/04/la-sicurezza-dei-farmaci-biologici-per-la-psoriasi/ 2020-09-14T08:31:59+00:00 https://www.farmacovigilanzasardegna.it/2019/10/04/sigaretta-elettronica-analisi-di-sicurezza-in-ambito-dermatologico/ 2020-09-14T08:31:59+00:00 https://www.farmacovigilanzasardegna.it/2019/10/11/summit-globale-per-la-vaccinazione/ 2020-09-14T08:31:59+00:00 https://www.farmacovigilanzasardegna.it/2019/09/27/la-sicurezza-dei-radiofarmaci/ 2020-09-14T08:32:00+00:00 https://www.farmacovigilanzasardegna.it/2019/09/27/la-sicurezza-dei-farmaci-dermatologici-durante-la-gravidanza-e-lallattamento/ 2020-09-14T08:32:00+00:00 https://www.farmacovigilanzasardegna.it/2019/09/13/la-terapia-anti-androgenica-e-il-rischio-di-malattie-cardiovascolari/ 2020-09-14T08:32:00+00:00 https://www.farmacovigilanzasardegna.it/2019/09/13/terapia-sostitutiva-in-menopausa-carcinoma-mammario/ 2020-09-14T08:32:00+00:00 https://www.farmacovigilanzasardegna.it/2019/09/20/sicurezza-di-macrolidi-e-fluorochinoloni-in-ambito-cardiovascolare/ 2020-09-14T08:32:00+00:00 https://www.farmacovigilanzasardegna.it/2019/09/20/la-farmacogenomica-e-i-farmaci-biologici-la-prospettiva-delle-agenzie-regolatorie/ 2020-09-14T08:32:00+00:00 https://www.farmacovigilanzasardegna.it/2019/09/06/associazione-tra-tramadolo-e-ipoglicemia/ 2020-09-14T08:32:01+00:00 https://www.farmacovigilanzasardegna.it/2019/09/06/raccomandazioni-per-larruolamento-di-donne-in-stato-di-gravidanza-nelle-sperimentazioni-cliniche/ 2020-09-14T08:32:01+00:00 https://www.farmacovigilanzasardegna.it/2020/10/01/ema-avvia-la-prima-revisione-ciclica-di-un-vaccino-anti-covid-19-nellue-1-ottobre-2020/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/10/05/i-regolatori-eu-ribadiscono-pienamente-gli-standard-di-trasparenza-ed-per-i-trattamenti-ed-i-vaccini-anti-covid-19-5-ottobre-2020/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/10/01/presentato-il-rapporto-aifa-sulluso-dei-farmaci-in-gravidanza/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/09/18/comunicazione-ema-sulluso-del-desametasone-nei-pazienti-covid-19-18-settembre-2020/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/09/23/nota-informativa-importante-su-nulojix-belatacept-23-settembre-2020/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/10/02/anticoagulanti-orali-diretti-e-malattia-polmonare-interstiziale-dati-emergenti-di-farmacovigilanza/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/anticoagulanti-79985.660x368.jpg https://www.farmacovigilanzasardegna.it/2020/09/11/evidenza-attuale-sullabuso-e-il-misuso-dei-gabapentinoidi/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/09/dolore.jpg https://www.farmacovigilanzasardegna.it/2020/09/18/rischio-di-ospedalizzazione-associato-con-benzodiazepine-e-z-drugs-in-italia-studio-multicentrico-nei-dipartimenti-di-emergenza/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/09/pillolePlacebo-e1601024201590.jpg https://www.farmacovigilanzasardegna.it/2020/09/18/vaccino-per-linfluenza-stagionale-e-rischio-sindrome-di-guillain-barre/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/09/logo_neurology.jpg https://www.farmacovigilanzasardegna.it/2020/09/25/segnalazione-delle-reazioni-avverse-in-africa/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/09/logo_InternationalJournalClinicalPharmacy.jpg https://www.farmacovigilanzasardegna.it/2020/10/01/ema-ricorda-ai-medici-di-usare-tecentriq-con-nab-paclitaxel-per-il-trattamento-del-cancro-al-seno-1-ottobre-2020/ 2020-10-08T07:28:09+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/09/02/comunicazione-ema-su-dexamethasone-taw-02-settembre-2020/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/09/04/comunicazione-ema-su-ulipristal-acetato-4-settembre-2020/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/09/10/nota-informativa-importante-su-diosmectal-diosmectite-10-settembre-2020/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/08/21/farmacovigilanza-news-sardegna-bollettino-luglio-2020/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/08/Bollettino2020luglio_img.jpg https://www.farmacovigilanzasardegna.it/2020/08/21/differenze-di-genere-nella-farmacocinetica-correlano-con-le-reazioni-avverse-da-farmaco-nelle-donne/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/08/logo_biolofySexDifferences.jpg https://www.farmacovigilanzasardegna.it/2020/08/28/e-learning-in-farmacovigilanza-buona-ricezione-dei-moduli-sviluppati-dalluppsala-monitoring-centre/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/08/umc.jpg https://www.farmacovigilanzasardegna.it/2020/08/28/associazione-tra-esposizione-a-inibitori-del-tumor-necrosis-factor-ed-eventi-infiammatori-del-sistema-nervoso-centrale/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/08/MAP-e-sclerosi-multipla-2-scaled-1.jpg https://www.farmacovigilanzasardegna.it/2020/09/04/percezione-del-paziente-delle-reazioni-avverse-ai-farmaci-biologici-per-le-malattie-infiammatorie-immuno-mediate/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/2020/09/04/dieci-anni-di-vaccinovigilanza-in-italia-uno-sguardo-sui-dati-di-farmacovigilanza-dal-2008-al-2017/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/09/5440812_1619_vaccini.jpg https://www.farmacovigilanzasardegna.it/2020/09/04/associazione-tra-la-somministrazione-di-corticosteroidi-sistemici-e-mortalita-nei-pazienti-critici-malati-di-covid-19/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/09/jama.jpg https://www.farmacovigilanzasardegna.it/2020/09/11/impatto-di-basse-dosi-di-litio-in-un-contesto-di-trattamento-delle-dipendenze/ 2020-10-08T07:28:10+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/09/20190610-litio-depressione-pleinair.jpg https://www.farmacovigilanzasardegna.it/2020/07/29/nota-informativa-importante-su-luxturna-voretigene-neparvovec-29-luglio-2020/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/07/30/nota-informativa-importante-su-prodotti-contenenti-leuprorelina-a-rilascio-prolungato-30-luglio-2020/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/07/31/comunicazione-aifa-sulle-sulle-buone-pratiche-di-somministrazione-dei-gas-medicinali-e-o-miscele-di-gas-medicinali-31-luglio-2020/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/08/20/nota-informativa-importante-su-erwinase-crisantaspase-20-agosto-2020/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/07/31/rapporto-aifa-2020-sulluso-dei-farmaci-durante-lepidemia-covid-19/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/07/AIFA_Rapporto_uso_farmaci_durante_epidemia_COVID-19-pdf.jpg https://www.farmacovigilanzasardegna.it/2020/08/07/accessi-al-pronto-soccorso-legati-a-reazioni-avverse-da-farmaco-12-anni-di-sorveglianza-attiva/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/2020/07/31/note-informative-importanti-aifa-ema-luglio-2020/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/11/aifa-n.jpg https://www.farmacovigilanzasardegna.it/2020/07/31/reazioni-avverse-immuno-correlate-verso-inibitori-dellimmuno-checkpoint/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/2020/08/07/in-corsi-di-sviluppo-le-linee-guida-nice-per-la-gestione-del-dolore-cronico-primario/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2016/09/NICE.png https://www.farmacovigilanzasardegna.it/2020/08/14/ketamina-esketamina-ruolo-nella-depressione-maggiore-e-profilo-di-sicurezza/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/08/logo_expertOpinionDrugSafety.jpg https://www.farmacovigilanzasardegna.it/2020/08/14/tamsulosina-e-rischio-di-demenza/ 2020-10-08T07:28:11+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/09/logo_PharmacoepidemiologyDrugSafety.jpg https://www.farmacovigilanzasardegna.it/2020/07/03/mezzi-di-contrasto-e-rischio-di-reazioni-di-ipersensibilita-richiamo-alle-precauzioni-da-adottare/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/11/aifa-n.jpg https://www.farmacovigilanzasardegna.it/2020/07/10/erenumab-nella-emicrania-cronica-refrattaria/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/07/logo_HeadachePain.jpg https://www.farmacovigilanzasardegna.it/2020/07/17/pregabalin-e-peggioramento-dellinsufficienza-cardiaca/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/01/logo_DrugSafety.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2019/01/logo_DrugSafety.jpg https://www.farmacovigilanzasardegna.it/2020/07/24/uppsala-monitoring-center-report-n-82-machine-learning-e-reazioni-avverse-da-farmaco/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/2020/07/09/ema-finalizza-il-parere-sulla-presenza-di-nitrosammine-nei-medicinali-09-luglio-2020/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/07/22/medicinali-contenenti-oppioidi-ridefinizione-dei-tempi-di-implementazione-delle-nuove-avvertenze-da-aggiungere-sulle-etichette-22-luglio-2020/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/07/24/lema-avvia-la-revisione-di-desametasone-per-il-trattamento-degli-adulti-affetti-da-covid-19-che-necessitano-di-supporto-alla-respirazione-24-luglio-2020/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/07/24/panexcell-clinical-laboratories-sospesi-i-medicinali-a-causa-di-studi-inattendibili-24-luglio-2020/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/07/24/gli-usi-autorizzati-del-medicinale-per-il-cancro-yondelis-rimangono-invariati-a-seguito-di-revisione-dei-nuovi-dati-24-luglio-2020/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/07/20/nota-informativa-importante-sulluso-di-medicinali-a-base-di-montelukast/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/2020/07/20/mezzi-di-contrasto-e-rischio-di-reazioni-di-ipersensibilita-richiamo-alle-precauzioni-da-adottare-2/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/2020/07/24/possibile-associazione-tra-integratori-a-base-di-curcuma-e-danno-epatico/ 2020-10-08T07:28:12+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/02/logo_BritishJClinicalPharmacology-2.jpg https://www.farmacovigilanzasardegna.it/2020/05/15/la-terapia-anticoagulante-in-corso-di-sars-cov2/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/05/15/ipomagnesemia-indotta-da-farmaco/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/05/22/eventi-avversi-cutanei-dei-farmaci-sperimentali-anti-covid-19/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/05/22/ridurre-gli-eventi-avversi-da-farmaco-selezionando-la-chiralita-di-una-molecola/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/05/29/clorochina-e-idrossiclorochina-nel-trattamento-di-covid-19-evidenze-a-sfavore/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/05/31/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-maggio-2020/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/05/30/covid-19-sospensione-duso-per-clorochina-e-idrossiclorochina/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/06/05/lumateperone-antipsicotico-con-ridotti-effetti-avversi-metabolici-di-risperidone/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/06/05/le-nitrosammine-un-probabile-agente-carcinogeno-presente-in-alcuni-farmaci-in-commercio/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/06/19/danni-al-fegato-indotti-da-farmaci-e-covid-19/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/2020/06/29/guida-al-buon-uso-degli-antibiotici-fluorochinolonici/ 2020-10-08T07:28:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/04/17/le-dirigenti-donna-sono-piu-efficienti-nel-ritirare-una-farmaco-scadente-dal-mercato/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/04/17/quando-il-sesso-fa-la-differenza/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/04/24/15272/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/04/24/newsletter-who-sulla-sicurezza-dei-farmaci/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/04/30/covid-19-trattamento-con-idrossiclorochina-e-azitromicina-associato-ad-anomalie-elettrocardiografiche/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/04/30/15286/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/04/30/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-aprile-2020/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/05/08/covid-19-e-potenziali-terapie-farmacologiche-focus-sulla-azitromicina/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/05/08/covid-19-in-che-modo-ema-accelera-il-supporto-allo-sviluppo-e-lapprovazione-di-medicinali-e-vaccini/ 2020-10-08T07:28:14+00:00 https://www.farmacovigilanzasardegna.it/2020/03/20/le-reazioni-avverse-da-farmaco-il-punto-di-vista-del-paziente/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/03/20/la-prevenzione-degli-avvelenamenti-nei-bambini/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/03/27/farmaci-falsificati-e-farmacie-non-autorizzate-ai-tempi-del-covid-19/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/03/27/cosa-succede-quando-assumiamo-due-o-piu-farmaci-insieme/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/04/03/farmaci-sperimentali-per-il-trattamento-di-covid-19-e-loro-interazioni-farmacologiche/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/03/31/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-marzo-2020/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/04/03/utilizzo-degli-antimalarici-clorochina-e-idrossiclorochina-nella-terapia-del-covid-19/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/04/10/statine-e-disturbi-cognitivi-il-possibile-ruolo-delleta/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/04/10/predire-la-tossicita-cardiaca-di-un-nuovo-farmaco-grazie-a-modelli-computazionali/ 2020-10-08T07:28:15+00:00 https://www.farmacovigilanzasardegna.it/2020/02/07/studio-italiano-sulle-interazioni-farmacocinetiche-di-interesse-clinico-tra-anticoagulanti-orali-diretti-e-farmaci-antiepilettici/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/14/leffetto-dei-corticosteroidi-sulla-mortalita-dei-pazienti-con-polmonite-influenzale/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/14/linee-guida-per-le-misure-di-prevenzione-del-coronavirus-di-tipo-non-farmacologico/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/21/differenze-legate-al-sesso-sulla-sicurezza-di-metformina/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/21/anticorpi-anti-tnfalfa-nelle-malattie-infiammatorie-intestinali-pediatriche-reazioni-avverse-neurologiche/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/28/amoxicillina-e-meningite-asettica-maschi-piu-a-rischio/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/28/desogestrel-e-attacchi-di-panico/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/02/28/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-febbraio-2020/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/03/06/i-glucocorticoidi-nellartrite-reumatoide-possono-causare-riduzione-della-massa-muscolare/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/03/06/errori-di-prescrizione-dopo-dimissione-ospedaliera-quanto-e-frequente-il-fenomeno/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/03/13/la-fragilita-dellanziano-e-la-sicurezza-dei-farmaci/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/03/13/sicurezza-ed-efficacia-dei-probiotici-vaginali/ 2020-10-08T07:28:16+00:00 https://www.farmacovigilanzasardegna.it/2020/01/31/aifa-ema-notizie-sulla-sicurezza-dei-farmaci-gennaio-2020/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/01/31/valutazione-delle-reazioni-avverse-agli-anticoagulanti-orali-diretti-registrate-nella-rete-nazionale-di-farmacovigilanza-mediante-un-indice-di-rischio/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/01/31/esposizione-a-infliximab-durante-la-gravidanza-esperienza-post-marketing/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/02/07/psoriasi-dopo-esposizione-a-inibitori-dellenzima-di-conversione-dellangiotensina/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/01/24/reazioni-di-ipersensibilita-sistemica-ai-nuovi-anticoagulanti-orali-review-della-letteratura/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/01/17/studio-post-marketing-sui-rischi-della-quetiapina/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/01/17/efficacia-e-sicurezza-del-cambio-tra-originatore-e-biosimilare-di-epoetine-in-pazienti-con-insufficienza-renale-cronica-studio-italiano-di-coorte/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/01/24/studio-sullassociazione-tra-anticorpi-monoclonali-e-idee-e-comportamento-suicidari/ 2020-10-08T07:28:17+00:00 https://www.farmacovigilanzasardegna.it/2020/10/06/ema-avvia-la-seconda-revisione-ciclica-di-un-vaccino-anti-covid-19-nellue-6-ottobre-2020/ 2020-10-12T11:10:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/10/09/il-ruolo-dei-media-nella-diffusione-di-fake-news-sui-farmaci/ 2020-10-13T10:19:30+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/logo_americanSocietyClinicalPharmacologyTherapeutics.jpg https://www.farmacovigilanzasardegna.it/2020/10/02/apixaban-una-revisione-sistematica-sulle-interazioni-farmacologiche/ 2020-10-16T08:16:13+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/coagulazione1.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/aa.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/bb.png https://www.farmacovigilanzasardegna.it/2020/10/16/sospensione-di-farmaci-per-motivi-di-sicurezza-una-revisione-dei-dati-che-supportano-la-decisione-di-sospensione/ 2020-10-16T11:08:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/hand-3632914_640.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/Cattura-2.jpg https://www.farmacovigilanzasardegna.it/2020/10/16/la-valutazione-della-sicurezza-dei-vaccini-per-il-covid-19-metodologia/ 2020-10-16T11:14:38+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/covid-4948866_640.jpg https://www.farmacovigilanzasardegna.it/2020/10/15/adozione-definitiva-della-nota-97-su-terapia-anticoagulante-nei-pazienti-con-fanv-15-ottobre-2020/ 2020-10-16T11:56:36+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/10/16/le-autorita-regolatorie-dellue-richiedono-di-testare-le-quantita-di-nitrosammine-per-i-farmaci-a-base-di-metformina-16-ottobre-2020/ 2020-10-16T11:59:59+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2015/05/Logo-EMA.jpg https://www.farmacovigilanzasardegna.it/2020/10/16/interazioni-farmaco-farmaco-tra-anticoagulanti-orali-diretti-e-agenti-antivirali-ad-azione-diretta-dellepatite-c-una-revisione-sistematica/ 2020-10-20T14:09:50+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/drug-4938120_1920.jpg https://www.farmacovigilanzasardegna.it/2020/07/17/campagna-farmacovigilanza-in-sardegna-2020/ 2020-10-21T10:55:39+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/07/logo_campagnaSegnalazioneSassari.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/files/2020/07/Volantino-farmacovigilanza-responsabili-locali.jpg https://www.farmacovigilanzasardegna.it/2020/10/23/efficacia-e-sicurezza-di-glecaprevir-pibrentasvir-per-il-trattamento-di-pazienti-con-infezione-cronica-da-hcv-una-meta-analisi/ 2020-10-23T11:22:16+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/523_image-1-e1603451525263.gif https://www.farmacovigilanzasardegna.it/2020/10/23/valutazione-della-sicurezza-cardiovascolare-dei-farmaci-anti-osteoporosi/ 2020-10-23T11:34:47+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/knee-1406964_1920.jpg https://www.farmacovigilanzasardegna.it/2020/10/09/esposizione-intrauterina-ai-farmaci-biologici-nelle-malattie-autoimmuni-infiammatorie-una-revisione-sistematica-sulla-sicurezza/ 2020-10-23T11:38:35+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/pregnant-2640994_1920.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/image.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/image-1.png https://www.farmacovigilanzasardegna.it/2020/10/23/comunicazione-su-medicinali-contenenti-rifampicina-23-ottobre-2020/ 2020-10-26T10:48:20+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/AIFA_Logo_2020.png https://www.farmacovigilanzasardegna.it/2020/10/29/segnalazione-di-eventi-di-sicurezza-durante-il-trattamento-anti-vegf-farmacovigilanza-in-uno-studio-non-interventistico/ 2020-10-29T12:51:48+00:00 https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/eye-369557_1920.jpg https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/image-2.png https://www.farmacovigilanzasardegna.it/wp-content/uploads/2020/10/image-3.png